“It’s cancer.”
IN 2015, MORE THAN 1.6 MILLION PEOPLE IN THE UNITED STATES FACED A CANCER DIAGNOSIS.

AT MSK, WE’RE LEADING THE WAY IN SETTING STANDARDS FOR THE DELIVERY AND QUALITY OF CANCER CARE NATIONWIDE.
## CONTENTS

**Message from the Chairman and the President**
04  

**OUTSMARTING CANCER**
08  

**THE RIGHT TREATMENT AT THE RIGHT TIME**
20  

**PATIENT COMFORT AND SATISFACTION**
32  

**INCREASING AND IMPROVING ACCESS TO CARE**
44  

**JOSIE ROBERTSON SURGERY CENTER**
58  

---  

**Statistical Profile**  
64  

**Financial Summary**  
66  

**Boards of Overseers and Managers**  
68  

**Leadership**  
69  

---  

**The Campaign for Memorial Sloan Kettering**
71  

**Donors to the Campaign for Memorial Sloan Kettering**
72  

**The Society of Memorial Sloan Kettering Cancer Center**
87  

---  

Medical oncologist and breast cancer expert Tiffany Traina with her patient Tracy Friedman
Message from the Chairman and the President

To enhance care delivery and extend our expertise to more patients, in 2015 Memorial Sloan Kettering embarked on a bold expansion of our facilities and implemented powerful new technologies that more efficiently and precisely attack cancer.
MSK is the nation’s first cancer hospital. That legacy continues to drive our focus on generating meaningful discoveries that change our understanding of cancer as a disease and applying those insights to improve the effectiveness of cancer treatment. MSK’s 2015 Annual Report takes improving outcomes as a broad theme because it touches every aspect of our work, from the bedside to the laboratory.

While the oncology community continues to make gains in cancer research and treatment, there are noteworthy gaps in achieving exceptional care for patients. The quality and cost of cancer treatment are inconsistent across the nation and survival rates vary widely. Indeed, an important recent study by researchers in Memorial Sloan Kettering’s Center for Health Policy and Outcomes and other MSK colleagues showed that Medicare patients treated at freestanding cancer centers have significantly better outcomes than those treated at community-based hospitals. The need to develop more effective strategies to prevent, detect, and treat cancer remains urgent. But these findings remind us that we have an equally pressing imperative: to bring together patients, clinicians, insurers, and policy experts to develop new approaches to providing cancer treatment.

MSK remains at the leading edge of immuno-oncology. From pioneering research into immune regulation, our physicians and scientists introduced the concept of immune checkpoint blockade therapy. Today, drugs that target immune checkpoints are unleashing the power of the immune system to detect and eradicate cancer. These same concepts have also led to the reengineering of patient T cells to specifically recognize tumors. And early in 2016, MSK became a founding member of the Sean Parker Institute for Cancer Immunotherapy, which will accelerate the pace at which these new applications are developed.

MSK-IMPACT® — a test created by our genome scientists, bioinformaticians, and molecular pathologists — detects gene mutations and other aberrations in both rare and common cancers. Since 2014, the test has sequenced more than 10,000 patients’ tumors. Data generated by this effort are enabling MSK scientists to better understand how specific mutations affect both cancer treatment and disease progression, thus changing how cancer is treated. A landmark study published in 2015 in the New England Journal of Medicine by MSK authors David Hyman and José Baselga illustrated how MSK-IMPACT data could be used to group patients whose tumors shared the same mutation — regardless of where their cancer originated. It represented the first “basket trial,” in which treatment was based on the mutation in a patient’s tumor rather than on the site where that tumor developed. (To learn more, read “Outsmarting Cancer” beginning on page 8.)

Researchers are also combining this wealth of MSK-IMPACT genomic data with information about family history and inherited genetic mutations as part of the Robert and Kate Niehaus Center for Inherited Cancer Genomics. The goal of the Niehaus Center, led by Kenneth Offit, Chief of the Clinical Genetics Service, is to identify opportunities to diagnose hereditary cancers at their earliest, most curable stages — the equivalent of a cancer genomics prevention program.

In late 2015, we began seeing patients at our magnificent new Josie Robertson Surgery Center, which has been specially designed to allow patients to return home either the day of or the day after a surgical procedure. You can read more about the facility, as well as the contributions our cadre of nurses made to its development, beginning on page 58.
Chemical biology is bringing new analytic techniques, molecular probes, and potential therapeutic leads to biomedical research and to cancer research in particular. To take full advantage of this, we created the Chemical Biology Program within SKI under the outstanding leadership of chemist Derek Tan in 2015.

To further the development of models for precision cancer treatment, Scott Lowe, Chair of the Cancer Biology and Genetics Program, and David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, were awarded a five-year, $10 million grant to support the use of genomic, computational, and animal modeling to more closely investigate specific cancers.

These are just a few examples that prove the adage that an organization is made stronger and more vibrant by the collective contributions of a diverse and talented staff. MSK itself received a significant honor reflecting the exceptional capabilities of our nurses. In early 2016, following a multiday site visit in December, the American Nurses Credentialing Center granted us Magnet recognition®, a distinction given to hospitals that demonstrate nursing excellence. This achievement confirms the superb performance of the entire nursing staff, led by Chief Nursing Officer Elizabeth McCormick, and marks the culmination of a years-long effort that involved MSK nurses at all levels.

MSK’s staff of more than 14,000 men and women gives selflessly of themselves to ensure our success. Each year we welcome new members to our family; 2015 was no exception.

Renowned clinician and genitourinary cancer researcher Philip Kantoff was one of our most noteworthy recruits. Dr. Kantoff joined MSK as Chair of the Department of Medicine after holding several leadership positions at...
is Chair of SKI’s Immunology Program. They join 19 other distinguished MSK scientists as members.

Our 2015 operating results were good. MSK’s operating revenues increased by 8.4 percent. Our operating expense growth was 11.4 percent, an increase reflective of pre-operating costs related to our expansion of our ambulatory care facilities. MSK’s operating expense growth during 2015 was also adversely impacted by the insolvency of a healthcare insurance company. (See page 66 for additional information on MSK’s operating results.)

In the following pages, we introduce you to a range of innovative approaches we’re taking to make care as accessible, coordinated, cost effective, and evidence based as possible to achieve the best outcomes for our patients.

By enhancing physician-patient communication, using patient feedback to improve care, illuminating the ways in which socioeconomic status affects treatment outcomes, and determining the right treatments for the right patients at the right time, we’re charting new territory and setting standards for the future.

Dana-Farber Cancer Institute and Harvard Medical School. He succeeded George Bosl, who served for 18 exemplary years as Chair.

We were delighted that Ned Groves came on board as Executive Vice President and Hospital Administrator. Previously, Mr. Groves served as Associate Director for Cancer Practice Administration and as Chief Operations Administrator for the Department of Oncology at the Mayo Clinic. He succeeded Kathryn Martin, now MSK’s Chief Operating Officer.

We also note with sorrow the untimely death in May 2015 of Alan Hall, Chair of SKI’s Cell Biology Program. He was a brilliant scientist with a deep and thoughtful intellect as well as a generous, good-humored, and respected colleague. He embodied the best that MSK has to offer and has been deeply missed. But his scientific contributions, the work of the many young scientists he trained, and his friendship to all remain an enduring legacy.

Our faculty was recognized with an abundance of awards in 2015, of which we’ll mention just a few.

- Lorenz Studer, Director of the Center for Stem Cell Biology and Member of SKI’s Developmental Biology Program, was named a MacArthur Fellow — one of just 24 people to receive a so-called “genius grant.”

- Maria Jasin, Member in the Developmental Biology Program, was elected to the National Academy of Sciences, joining 13 other MSK faculty members. The honor is one of the most prestigious a scientist can receive.

- Nikola Pavletich and Alexander Rudensky were both elected to the National Academy of Medicine. Dr. Pavletich is Chair of SKI’s Structural Biology Program; Dr. Rudensky

Douglas A. Warner III
Chair, Boards of Overseers and Managers

Craig B. Thompson
President and Chief Executive Officer
Research scholar Jie Su works in the laboratory of Sloan Kettering Institute Director Joan Massagué.
“What are you doing to learn more about cancer?”
Our laboratory-based and clinical research community is answering next-generation questions in cancer research and translating groundbreaking discoveries into more effective treatments for patients.
You don’t smoke. You’re not obese. You eat correctly. You exercise. You do everything you can to be a model citizen. And then you get cancer. Even with the best health practices, “we’re only going to be able to prevent about 40 percent of cancers,” says MSK Physician-in-Chief José Baselga. “We cannot escape the fact that the majority of cancers will occur because of the randomness of cell division.”

So what do we do? To borrow from the old joke about how one gets to Carnegie Hall — practice, practice, practice — in cancer, the punch line is research, research, research. No one can predict when or where the next major advance will occur, but it will always have its genesis in scientific investigation.

Three of MSK’s leaders — Dr. Baselga, Joan Massagué, Director of the Sloan Kettering Institute, and Charles Sawyers, Human Oncology and Pathogenesis Program Chair — have spent their lives gaining and sharing insights from their work in cancer biology and clinical and translational research. The multidisciplinary investigations in which they and their MSK colleagues engage are leading to the development of new cancer therapies and improved patient outcomes.
Nine out of every ten people who die from cancer die not from the primary tumor but because it spread to vital organs somewhere else in the body. This process of metastasis has been cancer’s black box. Little was known about its underlying causes.

According to Joan Massagué, an internationally recognized metastasis expert and Director of the Sloan Kettering Institute, in the past several years that black box has been opened wider than ever before — and MSK has played a key role in this. The Metastasis Research Center, which he directs, has brought together laboratories and scientists to facilitate metastasis study and treatment.
In his own lab, he and his colleagues have probed the basic causes of metastasis in a number of different cancers — such as breast, lung, and kidney cancer — and identified genes and pathways that give tumor cells the specialized traits they need to invade specific organs, survive in them, and spawn new tumors.

“Tumors release cells the moment they begin to form,” Dr. Massagué explains. Our immune system detects and kills most of them, but some escape detection and manage to infiltrate organs, where they live in the shadows — only to rear their heads years, even decades, later. The phenomenon is called latent (or dormant) metastasis.

Unfortunately, it’s all too common for cancer to return after what appears to be successful treatment. Roughly 25 percent of women with HER2-positive breast cancer will experience a recurrence following surgery and chemotherapy. For lung cancer patients the numbers are even starker — half will see their cancer come back.

You Can’t Hide Forever

A recent study by Dr. Massagué and colleagues published in the journal Cell describes how they’ve created a new model to understand latent metastasis and how they’ve used it to kick in the door — for the first time — exposing the mechanisms that allow these cells to hole up, waiting to emerge when they think the coast is clear.

“Young [latent metastasis] is the biggest untapped opportunity to have a major impact on cancer and patient outcomes,” he says. “But it’s hard to find latent cancer cells in the body, much less to figure out what makes them tick.”

You Can’t Hide Forever

Srinivas Malladi, a postdoctoral fellow in Dr. Massagué’s lab who was the study’s first author, spent six years developing the model and putting it to use. He began with tumor cells taken from patients with early-stage breast and lung cancers, which he labeled with a fluorescent tag. He then injected these cells into mice...
and waited. For months. Nearly all the transplanted cells died. But a few survived, and Dr. Malladi discovered they were hiding out in the lungs and the kidneys. He called these persistent survivors latency competent cancer (LCC) cells. With these surviving cells in hand, Dr. Malladi began to investigate what made them so furtive and able to avoid detection. His first clue came when he looked at the proteins the cells made. He found that LCC cells behave a lot like stem cells, which divide periodically to repair our tissues. This stem-like quality helps to explain the LCC cells’ ability to divide and seed distant organs.

Even more intriguing, though, he found that a proportion of these cells produce a protein that blocks cell division, forcing them into a state of suspended animation. This slowed-down growth is central to the cells’ ability to survive in the body without detection.

**Blinds Down, Lights Off**

It’s like evading the cops by pulling down the blinds in your apartment and turning off the lights: By not dividing, the LCC cells become less conspicuous to immune cells that patrol the body, looking for signs of trouble. When cells aren’t dividing, they don’t make the molecules that these immune cells detect, and so the immune cells ignore them. What’s more, most chemotherapies kill only dividing cells, which means that non-dividing LCCs can survive treatment.

Taken together, this explains why a few LCC cells are able to survive. These cells may also acquire additional mutations over time, allowing them to escape immune patrols completely and cause a cancer recurrence.

The idea that our immune system holds latent cancer in check is not new. But up until now, the mechanism through which latent cancer and the immune system battle it out had remained mysterious.

Now, this work from Dr. Massagué’s lab helps to clear up the mystery and suggests possible treatment options that may succeed where others have failed.

“Those of us who work on cancer and metastasis recognize we need all the help we can get — not only in terms of technology and resources but also in terms of sharing our knowledge,” Dr. Massagué says. “For me, there’s no better place than MSK for such sharing. Very few institutions in the world have the atmosphere it takes to address the broad and complicated questions we still face.”
“Precision medicine has emerged as an area of great promise in cancer treatment,” says José Baselga, MSK’s Physician-in-Chief. He is the leader of a landmark study published in 2015 in the *New England Journal of Medicine* showing one aspect of what this future looks like and demonstrating how it can work. The study, called a basket trial, showed that clinicians can design clinical trials based on genomics — the genetic mutations found in a tumor — rather than where in the body a cancer originated.

“As we’ve sequenced the genomes of more and more tumors, we have developed a catalog of genomic alterations, including those that drive particular cancers,” he says. If clinicians are able to match a mutation with a therapy that attacks it, it would change the way we conduct most cancer clinical trials. Until now, trials were designed by the site of origin, so clinicians would offer one drug to a lung cancer patient, another to a breast cancer patient, and so on.

“But we really need to listen to the biology,” says Dr. Baselga. What the biology has been saying to investigators is that it may be possible to treat multiple tumor types with the same therapy — as long as those tumors share the same mutation. The approach is dramatically reshaping ideas about clinical research.

**Listening to Biology**

*Something big is happening in precision cancer medicine and clinical trials that has far-reaching implications for the future of treatment and research.*
In addition to clarifying a treatment’s effectiveness in different tumor types, these basket studies provide an important opportunity to test therapies for rare cancers, which are severely underrepresented in clinical trials. Patients with rare disorders can enroll if they have the mutation under study.

**Written in Blood**

Blood tells a story. From discovering what we ingest to monitoring the functioning of our organs, from learning how well a drug is working to detecting diseases before they manifest symptoms, a vial of blood discloses many tales.

Tumors shed their DNA, circulating their secrets into a person’s blood. And now a breakthrough test called a liquid biopsy — a new alternative to tissue biopsy — holds the promise of a less invasive, more comprehensive way to deliver more-targeted cancer therapy and to monitor response to treatment.

Dr. Baselga has also been intimately involved in this work. Two 2015 MSK studies, one led by him and one that he co-authored with physician-scientist Sarat Chandarlapaty, demonstrated the potential of the liquid biopsy, which uses blood samples drawn from cancer patients to analyze trace amounts of free-floating tumor DNA.

If its use is validated in larger studies, a liquid biopsy will offer several advantages over a conventional tumor biopsy and could contribute to better patient outcomes, both in treatment and quality of life. It requires just a simple blood draw, and since surgery isn’t necessary, patients can be tested more frequently and with less discomfort and disruption of their daily activities. In addition, a liquid biopsy may provide a more global — and therefore more accurate — picture of the patient’s cancer, by capturing cancer cells from different parts of the body, including the primary tumor and metastases.

“You can study the evolution of the tumor and whether it’s responding to therapy in real time,” explains Dr. Baselga. “If you’re not getting the response you’re looking for, you can modify your approach.”

But it may also play a pivotal role in identifying cancers early. “In my mind, liquid biopsy is the most disruptive technology we’ve had in this field in years,” he says. “I can envision a future in which people will go to their doctor once a year and have a test that looks for the presence of tumor DNA in their blood. This would lead to a paradigm shift in early diagnosis.”

---

**Hurdles remain in cancer research. But I’ll take all the challenges because in my mind they pale in comparison to the opportunities.”**

—JOSE BASELGA

---

![Dr. Baselga meets with his patient Denise Albert.](image-url)
In January 2016, in his final State of the Union address, President Barack Obama announced the National Cancer Moonshot Initiative to improve cancer care and research. He appointed Vice President Joseph Biden to spearhead the effort. “The president’s call to action was a great opportunity for the entire oncology community to kind of hit ‘reset’ and ask, ‘How can we do this better?’” says Charles Sawyers, Chair of MSK’s Human Oncology and Pathogenesis Program.

There is a golden opportunity to make swift progress through sharing the clinical genetic sequencing data that cancer centers around the nation and the world are generating. Genes hold a vital key to our understanding of cancer and its underlying causes. A technology called next-generation sequencing, which significantly improves upon older gene-sequencing methods, is revolutionizing the way cancer research is conducted.

“The amount of information we’re getting is amazing,” says Dr. Sawyers. “But the quantity of data that genomic sequencing is producing has cancer researchers figuring out the best ways to analyze it all. We realized that to really leverage the information, we needed to band together.”

And so, well before the president issued his call to action, MSK and other cancer centers had already begun to craft a data-sharing effort: an unbiased, unaffiliated, nonprofit organization set up to convene the conversation and to house the data.

Summon the GENIE

The Genomics Evidence Neoplasia Information Exchange — Project GENIE — is an international initiative that includes MSK and six other leading cancer institutions, and is spearheaded by Dr. Sawyers. The American Association for Cancer Research, of which he is a past president, helped create the program.
“The need for Project GENIE is undeniable,” he says. “Numerous factors are driving an increase in the amount of genomic data available for analysis. In addition, it’s difficult for one institution to collect enough data to make statistically significant connections between a particular mutation and a specific cancer, especially for tumors and mutations that are rare. The numbers are just too small.” By aggregating existing and future genomic data from all seven participating institutions, it’s GENIE’s goal to address this problem.

There are many ways in which GENIE could affect patient outcomes, including:

- better predicting drug response and patient prognosis
- identifying new patient populations for previously FDA-approved drugs
- expanding the patient populations that may benefit from existing drugs
- identifying new drug targets and biomarkers

At the time GENIE was created, the database already held nearly 17,000 genomic records, and this number is growing quickly. Dr. Sawyers says that in the not-so-distant future, it’s likely that all cancer patients around the world could have their tumor genomics sequenced, and that their physicians could use a data registry to help make treatment decisions. “When this time comes, everyone involved in GENIE will know that he or she played a major role in bringing this new reality to life,” he says.

There is a golden opportunity to make swift progress through sharing the clinical genetic sequencing data that cancer centers around the nation and the world are generating. Genes hold a vital key to our understanding of cancer and its underlying causes.
Endocrinologist Michael Tuttle with his patient Pamela Murphy
“Am I getting the best treatment?”
One size doesn’t fit all. That’s why at MSK we’re committed to providing the right treatment for the right patient at the right time. It’s what precision cancer medicine is all about.
Most people’s first reaction to a cancer diagnosis is wanting to get rid of the disease as quickly as possible. When 47-year-old Nancy Hughes was diagnosed with follicular non-Hodgkin’s lymphoma in 2007, she went into fight mode — but her doctor had another idea.

MSK hematologic oncologist John Gerecitano instead recommended the “watch and wait,” or active surveillance, approach. Nancy, from Hampton Bays, New York, would be monitored regularly and put on chemotherapy only if her disease progressed.

As a result of decades of research, doctors now know that patients with certain types of cancer may not need immediate treatment. These patients are best served by active surveillance (also sometimes called watchful waiting). The approach usually involves regular testing to keep an eye on a tumor’s behavior over time. Only if symptoms develop or tests indicate the cancer is growing or changing is further treatment initiated.

“I remember thinking, This is insane. I have cancer, you have to get rid of it,” the mother of two recalls. “And I think that’s everybody’s initial response.”

That’s a reaction Dr. Gerecitano often finds himself receiving whenever he advocates a watch and wait approach for lymphoma patients. “This recommendation, especially in lymphoma, doesn’t mean we’re telling patients there’s no treatment for them,” he says. “We know from the data that harm will not come from waiting.”

Active surveillance is a common treatment strategy at MSK for lymphomas and other cancers that pose no immediate threat to a patient’s health.
“Some lymphomas can be treated like chronic conditions such as diabetes or high blood pressure, where we manage them over time,” says Dr. Gerecitano, who recently led a trial for venetoclax, a new FDA-approved lymphoma drug.

Even though that’s good news, many patients are skeptical about holding off on active treatment. “It causes understandable anxiety when you tell patients they have cancer but they should sit on the sidelines,” he says. “We live in a culture in which cancer is seen as an enemy that has to be actively fought.”

But the surveillance is called “active” for a reason. Usually, patients are first assessed every three to six months. Once doctors understand the disease’s growth pattern, they can sometimes space patients’ visits further apart — but they’re always carefully monitored.

At MSK, lymphoma experts typically recommend active surveillance for around 30 percent of patients. However, if and when a slow-growing lymphoma progresses, “it’s not one-size-fits-all,” says medical oncologist and lymphoma expert Alison Moskowitz. “Our choice of therapy depends on the individual patient and characteristics of the disease.”

When determining a treatment approach, Dr. Moskowitz and her colleagues are taking a mental look into each patient’s future. “We’re never thinking, OK, what am I going to do right now? We’re assessing our choices more broadly and long term,” she says. “We’re asking, ‘What am I going to do now, and then what am I going to do if I need to treat this person again? What are my next three steps?’ We want both to help prevent patients from developing treatment resistance and to ensure that they remain eligible for future therapies. Our goal is to deliver precisely the care our patients require — not too much, not too little, and only when they truly need it.”

When you go in for your appointments, those can be a little anxiety producing. But as time progresses it just gets easier to process.”

—NANCY HUGHES
It’s not a simple matter to explain to a person with cancer that immediate treatment may not be necessary, or even desirable. It’s a challenging conversation, says MSK urologic surgeon Behfar Ehdaie. “A cancer diagnosis is a call to action for most people, and they’re usually resistant at first to dealing with their disease in a non-interventional way,” he explains.

Active surveillance is important in prostate cancer because the treatments physicians use can negatively affect a man’s quality of life, so explaining the benefits is critical. Erectile dysfunction and urinary symptoms, including incontinence, are potential side effects of both surgery and radiation. “For the men we select for active surveillance, we’re offering them the opportunity to live without these side effects by monitoring their cancer, but more importantly to find a point at which a change in their tumor would lead to curative treatment,” Dr. Ehdaie says.

He and his colleagues recognized that improving their communication skills would help them increase the number of prostate cancer patients who would accept active surveillance as a treatment strategy. So they turned to an unusual source for assistance: a faculty member on the Negotiation, Organizations, and Markets Unit at the Harvard Business School.

To discover whether negotiation skills could play a role in physician-patient discussions, five surgical oncologists specializing in prostate cancer were recruited to participate in a one-hour training session with the Harvard consultant. The surgeons then applied the principles they’d learned during their training to patient conversations about active surveillance.

Among the behavioral science tools they were given is one that employs what’s known as “social proof,” highlighting for patients the choices that others in similar circumstances have made and their positive outcomes. Another is to talk about the natural history of prostate cancer — including its relatively long latency period — before even introducing a discussion of active surveillance. “This is very effective in overcoming patients’ perceptions that active surveillance is not aggressive enough, or that the cancer can metastasize between medical appointments,” says Dr. Ehdaie.
The results after instituting the new techniques were impressive: The proportion of candidates for active surveillance who selected the option increased from 69 percent in the 24 months before the intervention to more than 80 percent in the 12 months afterward.

Dr. Ehdaie and his colleagues are completing the study, which will further evaluate the success of the approach, and the results of which they expect to publish. “Our goal is that these skills can be taught to surgeons by surgeons — and, we hope, at institutions beyond MSK,” he says.

When a man comes to MSK with a prostate cancer diagnosis, his physician will first determine where he is in the course of his disease. This includes a review of his tumor pathology, including genetic testing to determine the risk of the tumor progressing in both the short and long term; the level of prostate-specific antigen (PSA) in his body; the results of a digital rectal exam; and an advanced imaging study, such as an MRI. If the MRI shows suspicious findings, he may also undergo an MRI-guided biopsy. If, after all these tests, the physician determines that a patient is at low risk, he can join the active surveillance program. Once in the program, “we do an examination of these men every six months and get a PSA level,” Dr. Ehdaie explains. “Every 18 months, we get an MRI of the prostate. If there are no changes, we continue seeing these patients every six months for three years. At that point, a man will get another MRI and an MRI-guided biopsy. We continue the imaging every 18 months, but we’re trying to minimize the number of biopsies a man has to undergo.” Most patients will have biopsies only once every three years. Most importantly, only 40 percent of MSK’s active surveillance prostate patients ever go on to need active treatment.

“We recently did a study in which we looked at what percentage of men with low-risk prostate cancer are offered and subsequently accept active surveillance at MSK. It turns out that 82 percent of our patients are and do, compared with a national average of about 40 percent in community health settings,” he concludes.

82% of MSK’s patients with low-risk prostate cancer accept active surveillance, compared with a national average of about 40% in community health settings.

Active surveillance is important in prostate cancer because the treatments physicians use can negatively affect a man’s quality of life, so explaining the benefits is critical.
Another group increasingly offered the benefits of active surveillance is patients with thyroid cancer. “When I was a fellow in the early 1990s, the only thyroid cancers likely to be diagnosed were lumps I could feel with my hands,” says MSK endocrinologist Michael Tuttle. “But around that time, better imaging options began to come onto the scene. And with that, screening that was done for other, unrelated reasons — but happened to show the thyroid area — often revealed tiny nodules.”

As a result of these more-sensitive scans and the increasing ability to biopsy these very small nodules, the reported rate of thyroid cancer in the United States has more than doubled since 1994. Yet despite this surge in detection and subsequent treatment, the death rate for thyroid cancer has not budged — an indication that these newly detected tumors were not life threatening.
“The majority of these very small thyroid cancers will never cause a problem,” Dr. Tuttle continues. “In fact, if the thyroid gland is very carefully examined, papillary thyroid cancer — the most common type of thyroid cancer — can be detected in more than 10 percent of healthy adults in the United States. But these tumors grow very slowly. They’re the same size in someone at 80 as they were at age 40.”

“All surgeries carry a level of risk,” says Dr. Tuttle. “Here at MSK, our complication rate is extremely low because our surgeons perform a high volume of thyroid operations.” Nationwide, however, about half of thyroid cancer removals are done by surgeons who perform fewer than ten a year. Patients whose thyroid is removed have to take hormones for the rest of their lives. “While most do fine,” he adds, “about 10 to 20 percent tell me they don’t feel good on the thyroid pills. They feel fatigued and have to work harder to function at their normal level.”

A new program at MSK gives certain patients with very early-stage thyroid cancer the option of choosing active surveillance in a program similar to what MSK’s prostate cancer patients are offered. If a person comes in with a small papillary thyroid cancer that appears to be confined to the gland and the thyroid cancer team feels that surgery is not required, that person is offered the opportunity to have an ultrasound exam every six months for two years instead of having the tumor removed.

“If after two years nothing has changed, we space out the ultrasounds to every nine to 12 months,” Dr. Tuttle explains. MSK physicians know that in the vast majority of cases, if thyroid cancer progresses, it’s going to happen slowly — in which case an operation will almost certainly be as effective in the future as it would have been at the time of diagnosis.

An international panel of physicians that included Dr. Tuttle and MSK pathologist Ronald Ghossein recently determined that a type of thyroid tumor that was classified as a cancer may not be a cancer at all. Their conclusion was published in the journal JAMA Oncology in April 2016. Once the diagnosis is confirmed by careful examination of the surgically removed thyroid nodule, these data confirm that no additional therapies are needed and exceptionally excellent outcomes can be expected in more than 99 percent of these patients.

Dr. Tuttle also points out that the American Thyroid Association guidelines, which he helped create, now recommend against taking biopsies of small thyroid nodules. “Even though you may know by looking at an ultrasound that the little spot you see is likely to be thyroid cancer, if you don’t stick a needle into it, you don’t turn your patient into a cancer patient,” he says. “The idea is that we want to decrease overdiagnosis. The message is, follow the guidelines. Don’t stick these little things. But even if you do, there’s almost never a reason to hurry into an operation.”
Mastectomy rates are rising in the United States — despite the fact that breast-conserving surgery has now been established as a safe option for many patients. More than three-quarters of women with newly diagnosed, early-stage breast cancer are candidates for this minimally invasive operation, called a lumpectomy, followed by radiation. During a lumpectomy, surgeons remove the tumor along with an area of normal tissue surrounding it — known as the surgical margin — to reduce the chance of leaving cancer cells behind.

Despite evidence that lumpectomy is as effective in treating breast cancer as mastectomy, many women are still not choosing the approach. For a long time, it was thought that this was the fault of surgeons simply not offering women breast conservation as an option. But that turns out not to be true. “The use of mastectomy in the United States is very heavily driven by patient preference, not medical necessity or doctor recommendation,” says Monica Morrow, Chief of the Breast Service in the Department of Surgery. “Our studies show that patients are choosing mastectomy in spite of the fact that they’re being given medical information that less-radical surgery is safe and effective.”

The fact is that with an invasive breast cancer, a mastectomy does not lower the risk of the cancer recurring at a distant site in the body, or even in the breast itself. “For most women with invasive breast cancer, the risk of the cancer recurring in the area of the surgery is the same whether they have a lumpectomy or a mastectomy,” she explains. “It’s driven by the biology of the cancer, not by which operation a woman has.”

The rate of bilateral mastectomy — surgery to remove both breasts — is also increasing dramatically. A study of MSK breast cancer patients by Dr. Morrow and her colleagues revealed that of women who had cancer in one breast but opted to have both removed,
only about 11 percent had high-risk cancer. “We would like to understand — from the woman’s perspective — why more of them are choosing this option,” she says, “especially at a time when adjuvant therapies [radiation, systemic chemotherapy, hormone therapy, and targeted drugs] have made the risk of developing cancer in the opposite breast lower than it’s ever been.”

And then there’s ductal carcinoma in situ (DCIS). DCIS is the presence of abnormal cells inside a milk duct in the breast. Accounting for roughly 20 percent of breast cancer cases, it’s called “in situ” (meaning “in place”) because the cells have not left the milk duct to invade nearby breast tissue. In itself, it’s not harmful. However, current imaging, clinical, pathological, and molecular tests don’t give surgeons the information they need to reliably predict which cases will turn into invasive cancer. And local recurrence rates — the return of DCIS in the same breast — remain substantial. Therefore, surgery with or without radiation therapy is recommended for the treatment of DCIS. “Whether we do a lumpectomy or a mastectomy is based on how much DCIS is in the breast,” says Dr. Morrow. “A small DCIS can be treated with a lumpectomy, but more widespread DCIS requires a mastectomy.”

Many patients with early-stage invasive breast cancer have to sort through adjuvant therapy options with their oncologists. “Today’s treatments are more individualized because we understand so much more about the biology of the disease,” says medical oncologist Tiffany Traina.

For breast cancers that are driven by estrogen, which represents the vast majority, doctors now routinely test a series of genes within the tumor to help them estimate the risk of recurrence for that particular cancer over the next 10 years. But what’s even more informative is the predictive value of the assay they use.

Doctors can now also predict what the benefit of chemotherapy will be for a woman with breast cancer and use that information to make smarter treatment choices. “At MSK, we are incorporating these new insights into tumor biology to help make the best treatment recommendations for our patients,” Dr. Traina says. “My colleagues and I are always conscious of how we can minimize the side effects of treatment while maximizing the benefits.”
Eliana Ortega, OR assistant, and Gregory Craigg, Manager of Perioperative Support Services, coordinate the day's surgeries in the main surgical center on the sixth floor of Memorial Hospital.
“I’m frightened. Will you take good care of me?”
Patients are at the center of everything we do. We’re constantly striving to improve patient satisfaction because good patient experiences are associated with better treatment outcomes.
When it comes to assessing patient satisfaction — specifically, how MSK patients rate their experiences in the hospital or ambulatory care settings — Kathryn Martin goes right to the data. As MSK’s Chief Operating Officer and an experienced hospital administrator, she wants to know what patients think, and she actually believes they ought to be more demanding.

Each quarter, more than 3,000 MSK patients are asked to participate in external surveys administered by Press Ganey, a leader in the field. The surveys encompass both inpatient and outpatient environments; the questions cover topics that range from room décor and staff courtesy to waiting times and emotional support.

Yet Ms. Martin focuses her attention on one key factor: care coordination — how well a patient’s care is managed across the different sites of care and among healthcare providers. “Patients’ assessment of how well we do coordinating care is the single best predictor of how well they rate their overall experience and whether or not they’d recommend us to their family and friends,” she says.

“Our goal is to integrate clinical excellence with service excellence,” Ms. Martin amplifies. “These insights guide our thinking about how outstanding clinical care and a superior experience converge to make a meaningful difference for patients and their families.”

Ms. Martin is proud of MSK’s track record. For example, more than 95 percent of hospital patients routinely report that they would recommend MSK, putting us in the upper ranks of all academic medical centers nationwide. Nonetheless, she sees room for improvement in how teams work together to coordinate patient care. “Patients want to feel like someone is in overall charge of their care and that all the staff they are in contact with are on the same page and wholly familiar with their particular needs,” she says. “We spend a great deal of time talking to our patients, but I always believe that we can and should do better.”

In addition to formal surveys, MSK seeks the patient perspective in a variety of other ways. Members of the Patient and Family Advisory Council for Quality (see opposite page) actively participate in hospital initiatives. Patient-reported outcomes and focused surveys have also been incorporated into the work of several disease management teams and the program at the Josie Robertson Surgery Center.
Members of MSK’s Patient and Family Advisory Council for Quality (PFACQ) — comprising current and former patients, family members, administrators, nurses, physicians, and patient representatives who meet monthly — are involved in numerous projects, quality improvement endeavors, and committees across the institution to ensure that patients’ and caregivers’ voices are heard.

Led by Chair Kate Niehaus, a former MSK patient, the council’s mission is to integrate the patient, family, and caregiver perspective into every aspect of MSK’s efforts to prevent, diagnose, treat, and cure cancer. In addition to their engagement with MSK initiatives, the group has initiated projects to address times of tremendous stress for families and caregivers — particularly points of transition in care — for new patients, for those finishing treatment, and for those transitioning into hospice. In one example, the team is working to find ways to better integrate the patient-to-patient program, which connects former patients with current ones for support and guidance, throughout patients’ care at MSK.

“The experts at MSK provide excellent care,” says Ms. Niehaus. “But we have a separate expertise that they don’t have — we know what it is to be a patient or a caregiver. And we want to use our expertise to help MSK set the standard for patient-centered care.”
Plastic and reconstructive surgeon Andrea Pusic and colorectal surgical oncologist Larissa Temple are experts in patient-reported outcomes. They lead MSK’s Patient-Reported Outcomes and Surgical Experience program, or PROSE.

PROSE was created to better understand how patients feel about their surgical treatment, care, and recovery. The program uses patients’ feedback about things like pain, symptoms after surgery, and level of functioning to help doctors make better-informed decisions about care — and to help them really understand what it’s like to be a patient. “There’s been a sea change from the idea that surgeons always know best,” says Dr. Pusic.

“Patients today want to be engaged in decision-making,” adds Dr. Temple. “The tools we’ve developed are based on what we hear from patients during in-depth interviews — so patients have truly contributed to their creation.”

Cancer experts are increasingly focusing on asking similar questions of patients involved in clinical trials. Studies have shown that they generally underreport their side effects, for several reasons — they may be focusing on competing issues, such as test results, or are just reluctant to share their symptoms. As a result, quality of life can suffer. Researchers are looking for ways to scientifically evaluate side effects to improve care for these patients.

Recently a team funded by the National Cancer Institute and led by investigators at MSK and several other cancer centers worked with patients to develop a system for measuring their experiences during clinical trials. The group published an analysis of the tool’s effectiveness in November 2015 in the journal JAMA Oncology.

It asks patients 124 questions about 78 potential side effects, including pain, fatigue, nausea, and skin problems — an unprecedented breadth of assessment, says Thomas Atkinson, head of MSK’s Behavioral Research Methods Core Facility and one of the study’s authors. “The largest stakeholder in clinical research is the patient,” he adds. “The majority of patients who participated in the study said that it helped them have better discussions with their doctors and nurses.”

“It’s not enough to save a life,” Dr. Pusic concludes. “It’s about the quality of the life you’ve saved.”
In 2005, MSK recognized that this issue needed addressing and established the Communications Skills Training and Research Program, or Comskil — the first structured communications initiative at a comprehensive cancer center. Comskil is designed to train physicians and other healthcare professionals to communicate in a patient-centered and effective way. The program began with attending physicians and oncology fellows and now includes both inpatient and outpatient nurses as well as other clinician groups.

Comskil training allows learners to hone their skills with trained actors playing roles in different scenarios that can range from dealing with an angry patient to comforting bereaved parents. An MSK communications skills expert and a member from the learners’ discipline who has received Comskil and facilitator training act as co-facilitators, with two or three trainees participating at a time.

Learning to Have Difficult Conversations

It's not enough to walk the walk. You need to be able to talk the talk. And that's a gift that doesn't come easily or naturally to everyone — even doctors and nurses.
Before each scenario, facilitators give the actors instructions, such as the intensity of the emotions they’d like them to display. At the conclusion, trainees view themselves on video to learn where they can make improvements. Trainees also receive feedback from their co-trainees, the facilitators, and even from the actors.

“A Comskil Focus on Pediatric Oncology Nursing

Over the past decade, Comskil training has been available for all MSK physicians, clinical fellows, and nurses. But Joe and Robin Kanarek — who lost their young son, David, to acute lymphoblastic leukemia — saw an opportunity to extend Comskil training to pediatric nurse practitioners through their Kanarek Family Foundation.

More than 55 pediatric nurse practitioners have taken the training. Nurse practitioner Anne Casson, a member of MSK’s Department of Pediatrics for 21 years, was David Kanarek’s nurse before, during, and after a stem cell transplant that was performed to try to treat his leukemia. She’s taken the Comskil training and is now a facilitator.

“None of us like having difficult conversations,” she says. “But if a child relapses and parents need to make end-of-life decisions, you need to have an honest dialogue with families. In Comskil training you learn to use the word ‘death,’ which is not easy for many of us. Comskil has become a very important part of our ongoing MSK training.”

“The Kanareks’ commitment to nursing, palliative care, and pediatrics made this Comskil project come into focus and be executed rapidly,” adds Julia Kearney, MSK pediatrician and child and adolescent psychiatrist. “Their dedication to the work is genuine, meaningful, and an inspiration to us.”

Our program covers issues that include breaking bad news, shared decision-making, responding to patient anger, discussing palliative care, working with interpreters, and transitioning to survivorship.”

—PATRICIA PARKER

“Our program covers issues that include breaking bad news, shared decision-making, responding to patient anger, discussing palliative care, working with interpreters, and transitioning to survivorship,” says Director Patricia Parker. Dr. Parker and her colleagues are also working on ways to expand their reach even further to offer training that meets the needs of anyone who interacts with patients.
“Each stage along the road of cancer treatment can represent a new crisis,” says Penelope Damaskos, Director of MSK’s Department of Social Work. “Social work runs the gamut, from helping people cope with the diagnosis and adjust to living with illness to assisting and supporting them in practical issues.”

A social worker is trained to help people deal not only with how they feel about a situation but also with what they can do about it. Dr. Damaskos explains, “Our aim is that every patient who comes through our doors has an opportunity to get help to better manage and understand the impact cancer has on their lives.”

MSK’s social workers can intervene in almost any aspect of a patient’s life. On the practical side, they have funds available to provide nontreatment financial assistance to people who may need it. For example, some patients need help getting to their appointments or temporary housing near the hospital. A patient who may require help with rent, utilities, or childcare can also look to social workers. (The lion’s share of these funds is provided by The Society of Memorial Sloan Kettering, a volunteer organization that offers a range of enhancements to MSK’s patient care and research programs.)

MSK’s social workers offer counseling as well. If a patient or family is experiencing an emotional crisis, their doors are open. “We help patients and families at this extremely vulnerable moment in their lives,” Dr. Damaskos says.
MSK’s Geriatrics Service in the Department of Medicine addresses the special challenges of treating cancer in older patients and serves as the focal point for ongoing clinical research.

In 2015, MSK established a geriatric education initiative to instruct physicians in how to most effectively treat cancer in older patients. The new program was made possible by a grant from the US Health Services Resources Administration. MSK was the only cancer hospital to receive one of these grants.

“Physicians are thinking about older adults and cancer very differently than they did years ago,” says MSK clinical psychologist Christian Nelson, who works with the 65+ Program, a multidisciplinary initiative comprising experts from various fields, including physical therapy, psychiatry, pharmacy, and social work. “We now commonly offer cancer treatment to people in their 80s and even 90s.” He points out that the age of the average cancer patient today is over 65, as is the average age of survivors.

The treatment preferences of older adults can differ from those of younger cancer patients. “In my experience, older adults may come in wanting to know even more than younger people about the range of treatment options,” Dr. Nelson says. “They are often more concerned with their quality of life as opposed to extending the length of that life.”

Interestingly, levels of emotional distress may be lower in older adults. “One reason is simply where they are in their lives,” he says. “The other reason is better coping skills: Older patients have experienced more ups and downs.”

However, older adults with cancer often face situations that affect them more profoundly than younger patients. They may be at an increased risk of social isolation due to circumstances such as living alone or acting as the primary caregiver for an aging spouse or partner. Suddenly, the caregiver needs care.

Dr. Nelson co-facilitates a support group for older patients called the Vintage Readers Book Club. “Because most of the members are vintage,” Dr. Nelson smiles. “Jimmie Holland [the first Chair of MSK’s Department of Psychiatry and Behavioral Sciences and a pioneer in psycho-oncology] has really taken the lead in this. Our readings have been very eclectic and range from Martin Luther King Jr.’s ‘Letter from Birmingham Jail’ to Cicero’s essay on aging. The idea is to give members another way to connect.”

“It’s a privilege to care for and work with older adults,” says Dr. Nelson. “I often think I learn more from them than they learn from me.”
Internist Deborah Korenstein with nurse practitioners Rosanne Sharp (left) and Maureen Reidy (right)
“How am I going to get the care I need?”
Providing access to cancer care is a complex challenge. At MSK, we turn challenges into opportunities. From screening for financial distress and connecting with the medically underserved to forming alliances with community-based providers, we’re extending care and improving outcomes for more patients than ever before.
A Conversation with Peter Bach

Physician Peter Bach is Director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes. He and his colleagues collaborate on research and analysis that embrace a wide range of cancer types and issues. Their aim is to contribute to the development of approaches that will improve patient outcomes. Here, he talks about measuring the complex and often profound impact treatments can have on patients and the ways in which we can better provide cost-effective cancer care.
What do we mean when we talk about outcomes as they relate to cancer?

In the broadest sense, cancer outcomes — and research to enhance those outcomes — encompasses the entire trajectory of the illness and evaluates all aspects of care. We consider a range of questions: How long do people live? How well do they live? Have we cured their cancer? How long do patients go on before the disease relapses or recurs? Also vital to outcomes research are the issues that surround making cancer care more efficient and cost effective.

Obviously, the most important of these is patient survival. Most of what we do in cancer is aimed at prolonging life. But quality of life is also extremely important. As we work to extend life, we want to do it in the safest way we can and with minimal side effects, so people can continue to live their lives as normally and comfortably as possible.

Finally, the reality of caring for people with cancer is also the reality of taking care of those who are dying. While this is not the outcome we wish for our patients, some of them will experience it, so end-of-life care is very much on the agenda of outcomes research.

One big focus of outcomes is overall survival rates, which may be quite different depending on where a patient is treated.

True. Research has shown that cancer survival outcomes can vary widely depending on where a patient receives care. But it’s been difficult to assess hospitals by long-term survival rates without including disease-stage information.

However, a study my colleagues and I published in October 2015 in *JAMA Oncology* found that readily available, unbiased Medicare claims data may be sufficient to calculate long-term survival rates at hospitals, eliminating the need to know the stage of individual patients’ cancers.

What did you discover?

In a nutshell, we found that there were large survival differences between different types of hospitals that treat Medicare patients with cancer. We discovered that patients treated at specialized cancer centers, including MSK, had a 9 percent higher survival rate over five years compared with cancer patients treated at community hospitals.

So that 9 percent represents deaths that might be prevented?

Yes. The degree of survival gap between hospital types is substantial and represents potentially preventable deaths. If more research confirms this survival gap, our next step will be to figure out the mechanics underpinning it.
Can where you’re treated affect your chances for survival?

Yes.

A recent MSK study of 750,000 patient treatment records from 2006-2011 showed that patients treated at specialized cancer centers had a 9% higher survival rate over five years than those treated at community hospitals, regardless of tumor type or stage.

Dr. Bach and his colleagues are now studying the factors behind these differences. The MSK study was conducted by a multidisciplinary clinical and administrative team including Dr. Bach; David Pfister, Chief of MSK’s Head and Neck Oncology Service; Elaine Duck; Elena Elkin; Ushma Neill; Mark Radzyner; and David Rubin.

Can you discuss what is known as comparative effectiveness research and how it benefits patient outcomes?

The whole idea of comparative effectiveness research is to identify ways in which you can do something that’s easier on a patient or less expensive — or both — and get the same quality outcomes as doing something more expensive or difficult.

For example, we can compare different surgical approaches for the same disease, or different radiotherapy approaches, or different approaches to diagnostic testing. These are all areas in which we can employ comparative effectiveness research to learn if we’re able to achieve the same outcomes at a lower cost, or even improve them.

Much of what you’ve talked about relates to issues of transparency.

It does. It’s part of our mission at MSK and it’s the right thing to do. Looking at hospital-specific cancer survival is the start of a very large effort to bring transparency to performance and to cost. It may be uncomfortable, but it’s vital.

You’ve received a great deal of press attention for the stance you’ve taken against the high cost of cancer drugs.

Right now we have a pricing system that has no checks in place. Pharmaceutical companies are allowed to charge whatever they like.

As a consequence, we’ve had more-rapid rises in pricing and spending on drugs than in any other category of healthcare. A few decades ago we used to be alarmed when cancer drugs cost $1,000 a month. Now we’re seeing drugs that cost $10,000 or $20,000 a month.

We’re developing an approach to pricing drugs based on their value, as defined by questions such as how much benefit they give patients, how much they contribute to survival, and what side effects they cause. Does a drug have a favorable profile? If it does, perhaps it should garner a somewhat higher price — but if it doesn’t, it shouldn’t.

Soaring drug costs are a serious problem. Here’s just one example: There are people in this country who are not getting Gleevec® [a drug used to treat chronic myelogenous leukemia and several other types of cancer] because the price is so high. This, in the wealthiest nation on earth, is somewhere between embarrassing and heartbreaking.
Cancer Care Cost and Value

Having the best care isn’t worth much if patients can’t afford to access it. “What we’re really talking about is giving good value,” says MSK Chief Operating Officer Kathryn Martin when asked about outcomes. “We spend a lot of time trying to communicate this to patients, referring physicians, insurance companies, and large employers — better outcomes at a hopefully lower cost, but at the very least no higher cost. This is a critical distinction between MSK and many other oncology providers.”

The economic burden of cancer on patients is a subject about which Ms. Martin is passionate. “If someone comes through our doors and says that he or she has a financial problem,” she says, “we’ll do everything possible to make sure that lack of money is not a barrier.”

In fact, the stress of what is sometimes called financial toxicity can be as significant as the physical toxicities of cancer treatment and can contribute to worse clinical outcomes and reduced quality of life. That’s why providing high-quality cancer care now includes assessing patients for financial distress. “As part of our screening tool for every new patient, our nurses ask, ‘Would you like to speak to someone about your ability to pay for treatment?’, and ‘Do you need help with transportation to medical appointments or temporary lodging during treatment?’” Ms. Martin explains.

If patients reveal they can’t afford treatment they are referred to MSK’s Financial Assistance Program, where patients with incomes up to five times the federal poverty level are eligible for help. Last year more than 1,000 patients had their bills reduced or eliminated because they could not afford to pay. Patients who are struggling with non-treatment-related costs such as rent, transportation, or childcare are referred to MSK’s Department of Social Work. Using gifts from The Society of MSK and other generous donors, in 2015 social workers were able to help more than 1,700 patients who were having trouble making ends meet. (To read more about social work, see page 42.)

MSK staff are engaged in many other efforts to reduce the cost of care and, in turn, the financial burden on patients. Ms. Martin makes the point that “the cost question” does not in any way conflict with patient care. Indeed, she says, “They’re totally aligned. We absolutely believe that cost-effective patient care is the highest-quality care.”
MEDICAL TESTING

DEBORAH KORENSTEIN
INTERNAL MEDICINE SPECIALIST

Changing the Culture

One way to cut costs without compromising outcomes is through the prudent use of medical tests. “The overuse of testing is usually framed as a cost problem,” says MSK internal medicine specialist Deborah Korenstein. “But to me, it goes much deeper. It’s really a fundamental quality-of-care issue, because everything you do — whether it’s prescribing a drug or a diagnostic test — runs the risk of harm. And if we’re not doing something that potentially benefits patients, then we’re simply exposing them to potential harm.”

For a number of years, Dr. Korenstein has been involved nationally in designing ways to measure how much unnecessary care doctors are giving to patients and trying to tease out why they do it. She observes that the cultural landscape of medicine contributes to the problem. “Traditionally, doctors have subscribed to the idea that something is better than nothing,” she says. “There was a sense that to be a heroic doctor meant to go above and beyond for your patient. However, there has never really been an acknowledgement or a quantification of the potential harms of that approach.”

Yet another barrier to changing medical practice is that when doctors are trained, “we’re taught not to miss anything,” she says. “Young doctors will generate long lists of what could possibly be wrong with a patient even though out of 25 things on the list, 21 of them are virtually impossible. And senior doctors grill junior doctors, ‘Did you do this? Did you order that?’ No one will ever get in trouble for having done too much or ordering too many tests.”

These factors can become magnified in cancer. “There’s the feeling that patients with cancer are very sick and extremely vulnerable,” Dr. Korenstein says. “People are worried about them — and that’s totally legitimate. But it cuts both ways: The harms of doing unnecessary things may be increased in cancer patients precisely because they are so vulnerable.”

She has recently initiated a project at MSK that addresses the overuse of laboratory testing in hospitalized patients. To launch it, she created a survey of staff who care for MSK’s inpatients, including floor nurses, nurse practitioners, physician assistants,
doctors in training, and attending physicians. Two key questions she asked were whether patients typically received unnecessary lab tests and whether staff would be comfortable with less testing. “Across the board, the majority of people said they would be comfortable doing less,” she says. And the most common reasons respondents gave for not actually reducing the number of tests? Habit.

Now Dr. Korenstein is working with a multidisciplinary committee to pilot a project on one service in Memorial Hospital to see if it can help cut down on excess lab testing. It’s an intervention that is strikingly simple: The group has created a small poster that hangs in the nurses’ station reminding clinical staff to consider what they’re ordering. Every week, she will send the staff a report of their “most popular tests,” as she puts it, and will track what happens. “The message is not ‘Don’t do it,’” she explains. “It’s ‘Think about it and only do the things your patient really needs.’”

She talks compellingly about what’s known as “anxiety due to uncertainty” and how this may affect medical decision-making. “Uncertainty is a huge part of being a doctor — you rarely know anything with 100 percent certainty,” she says. “And people who are more uncomfortable with uncertainty usually do more testing.”

Since arriving at MSK about a year ago, Dr. Korenstein says she is optimistic about the future. “Everyone has been so welcoming and open to the idea of trying to implement positive change.”

Traditionally, doctors have subscribed to the idea that something is better than nothing.... However, there has never really been an acknowledgement or a quantification of the potential harms of that approach.”

—DEBORAH KORENSTEIN
Going Where People Work, Play, and Learn

Internist Francesca Gany, Chief of MSK’s Immigrant Health and Cancer Disparities (IHCD) Service, doesn’t spend a lot of time in her office. That’s because her most important work is done in the community, connecting immigrants, minority community members, and the medically underserved with the healthcare system in an effort to eliminate cancer and health disparities.

Immigrants and minorities have disproportionately high rates of many types of cancer, but many do not have the resources to access quality care. Lack of access to health information and services has been shown to have a negative impact on treatment outcomes for the medically underserved. “The work of our service is to identify the causes of health disparities in these populations and to develop, implement, and test interventions to overcome them,” Dr. Gany says. The service also conducts outreach and education, delivers services to underserved communities, and trains practitioners and scientists who are members of those communities.

It comes as no surprise that the economic issues of cancer and its treatment can be staggering. But what may be eye opening is that among these problems is food. “Food is huge,” says Dr. Gany. “We’ve found that 60 percent of patients served by the Integrated Cancer Care Access Network are food insecure. The program gives immigrants with cancer access to quality care, services, and resources that help ease the financial burden of treatment, including indirect costs such as transportation, childcare, and food. This means patients may not be traveling to medical appointments so they can have that transportation money to feed their kids. Or their hourly jobs give them only enough money to feed their families. Or they’re barely eating. These
We’ve found that 60 percent of patients served by the Integrated Cancer Care Access Network are food insecure. These patients very often have worse treatment outcomes than those who have enough to eat.”

—FRANCESCA GANY

Individual Concerns, Personalized Programs

Each ethnic group has its own distinct set of health and cancer issues. IHCD has several programs that tackle some of the most pervasive of these concerns.

The Arab Health Initiative runs a breast cancer education and referral program that aims to disseminate culturally sensitive information about breast cancer to Arab-American women. In women diagnosed with breast cancer, IHCD staff helps them access healthcare services and provides psychosocial support.

The South Asian Health Initiative works to increase awareness and treatment of the most common health problems affecting the South Asian immigrant community, including oral cancer, diabetes, high blood pressure, and high cholesterol.

Ventanillas de Salud (Health Windows) was created by the Mexican Consulate as a venture between government and private organizations to eliminate barriers to healthcare in New York City’s growing Mexican-American population. “There’s a high incidence of cervical cancer in the Mexican-American community, and we currently have an initiative around cervical cancer and HPV vaccination,” says Dr. Gany. “We’re finding that we can increase HPV vaccination rates among the children of these immigrants and have gotten it up to about 70 percent — much higher than the national average.”

Community outreach assistant Anuradha Hashemi (left) and internal medicine specialist and public health researcher Abraham Aragones work with Dr. Gany on the Immigrant Health and Cancer Disparities Service.

patients very often have worse treatment outcomes than those who have enough to eat.”

That’s why IHCD established its Food to Overcome Outcome Disparities Program. The program distributes nourishing food to patients and their families through pantries located in Manhattan, Brooklyn, Queens, and the Bronx.

And then there’s a population that few consider, except on a cold, rainy day or after a late night at the theater: taxi drivers. There are more than 100,000 in New York City and almost all of them face similar health issues: obesity; a sedentary lifestyle behind the wheel; insulin resistance, which can lead to type 2 diabetes; and the heightened cardiovascular and cancer risks that accompany these conditions.

The Immigrant Health Service has a grant from the National Institute on Minority Health and Health Disparities to improve the health of New York City cab drivers. Dr. Gany and her colleagues have partnered with the South Asian Council for Social Services and have worked with an advisory board of taxi drivers, community partners, and an external advisory committee to assess drivers’ health priorities, identifying barriers to healthcare and finding ways to reduce health disparities in this community.

Their findings have informed the development of comprehensive driver-centric health interventions, such as using air filters to remove particulate matter in taxis; pedometers — in a project called Step On It — to increase driver activity levels; and healthcare coverage and access navigators to help drivers obtain and keep health insurance coverage. “Another of our goals is to make sure that every driver has a primary care physician,” says Dr. Gany. “Many of them don’t. And if a driver has a colonoscopy and is found to have cancer, we’re going to connect him or her with the appropriate care.”
The MSK Cancer Alliance now includes Hartford HealthCare, a multihospital system in Connecticut; Lehigh Valley Health Network in Pennsylvania; and the newest member, the Miami Cancer Institute, part of South Florida’s Baptist Health System. “Initially we thought of the Alliance as an opportunity to raise the standard of cancer care in the community for people who would not otherwise have access to the expertise of a comprehensive cancer center,” says Kathryn Martin, Chief Operating Officer. “But as the Alliance has evolved, we’ve come up with several other goals — and an important one is research, because with the advent of precision cancer medicine, our clinical care and research efforts are more closely aligned than ever.”
And, like Ms. Martin, he points to a revolution in personalized cancer medicine, with more patients required to fulfill a burgeoning research agenda. “Right now, we have about 800 clinical trials ongoing at MSK,” he says. “The Alliance is about taking these cutting-edge trials and opening them up to the community.” Not only will trials be available to many more patients who need them, but also, says Dr. Barakat, “by increasing the numbers of patients enrolled on these trials, we’re actually going to be able to answer the most burning questions in cancer much faster. We’ll be studying outcomes very closely, and our knowledge base is going to increase exponentially.”

“These are living, breathing, dynamic partnerships with a robust sharing of ideas and expertise,” says Richard Barakat, Deputy Physician-in-Chief for MSK’s Regional Care Network and the MSK Cancer Alliance. He and his colleagues have studied how Alliance members treat the six most common cancers to determine if MSK’s and members’ practices are in sync. “If they aren’t, we’ve come up with mitigation plans so that ultimately we’re all practicing in similar ways,” he explains. “We also have the ability for our disease management teams to work together. For example, Hartford, Miami, and Lehigh doctors will present cases at our tumor boards. What patients are getting is several healthcare systems interacting with MSK experts to decide the most-effective treatment approaches.”
Even before they enter the thoughtfully designed building on the day of their surgery, patients at the Josie Robertson Surgery Center (JRSC) have already embarked on a journey in which every step has been scrupulously planned to be as safe, smooth, and pleasant as possible.

“This unrivaled facility is the result of years of research by our experts that’s now been translated into the most effective and personal outpatient surgical care,” says Brett Simon, Director of the JRSC.

“Our goal is to offer our patients an unmatched experience while they are with us at the JRSC and then enable them to return home and resume their daily activities,” Dr. Simon says. “Designing a way to get them to that point safely and quickly is a significant advance in cancer care pioneered at MSK.”

For example, as patients approach the day of their procedure, an online patient portal enables them to communicate directly with medical staff, with a mobile device app planned to be available soon. They also receive notifications from the staff to familiarize them with the facility and instruct them on preparing for their operation.

The center was established with a gift of $50 million from the Robertson Foundation, established in 1996 by the late Josephine (Josie) Robertson and her husband, legendary investor Julian H. Robertson, Jr., and their family.
JOSIE ROBERTSON SURGERY CENTER
From left: The Josie Robertson Surgery Center offers gathering spaces for patients and their caregivers to relax before and after surgery; breast surgeon Carol Brown meets with a patient.

A Comfortable and Serene Setting

When patients arrive at the Josie Robertson Surgery Center on the day of their surgery, a concierge greets them in the lobby. Floor-to-ceiling windows let in abundant natural light and offer sweeping views of the East River. Once they’re checked in, a real-time location system gives patients the flexibility to move around, and staff can still find them when needed.

Specially designed areas allow family members and caregivers to rest, eat, read, go online, play games to let off steam, or just have a quiet moment. A patient and caregiver waiting area on the third floor includes a café, tables with board games and crossword puzzles, and an Xbox station for playing video games. Tables and chairs, clustered in small groups called campsites, enable people to be together while they wait to see their loved one.

Each short-stay patient room is private, with its own bathroom, and includes bedside tablets equipped with video conferencing technology to allow patients to continue securely...
communicating with their doctors, caregivers, and family and friends after surgery. If a patient needs to stay overnight, these rooms include sleeper sofas or chairs to accommodate a caregiver.

In addition, the center has been designed to inspire patients to get out of bed as soon as they can. Central gathering areas outside the patient rooms encourage them to socialize, relax, or have a buffet-style snack. In the corridors, artwork and inscriptions on the walls serve as walking milestones, so patients can track their progress in the hours following their operation.

Diligent Follow-Up

After surgery, patients are closely monitored as they recover in the facility and are then deemed ready to be sent home. But the JRSC’s commitment to patient care doesn’t end there. On the day after their discharge, all patients receive a phone call from a nurse checking on the progress of their recovery.

Medical staff then continues to check in electronically with patients on a daily basis to ensure that their recovery is going smoothly, answer questions, and address any issues that may arise. This daily symptom reporting also gives JRSC physicians, nurses, and clinical staff information that will help them learn from and reevaluate procedures, such as changing pain medication prescriptions or altering how anesthesia is given.

“The increased attention to follow-up at Josie Robertson really stands out,” says Rebecca Twersky, Chief of Anesthesia at the JRSC. “After patients go home, we check in with them constantly to guide their recovery. Then, using data from these interactions, we see how we can improve our care and enhance outcomes.”

Sophisticated Surgical Technology

The 12 operating rooms at the Josie Robertson Surgery Center have been equipped to perform specific surgeries, including robot-assisted procedures. Some of the most common operations performed here include breast surgery with immediate reconstruction and prostate, kidney, ovarian, uterine, and thyroid surgery.

“The operating rooms at the Josie Robertson Surgery Center feature state-of-the-art equipment incorporating the most-advanced technology available,” says urologic surgeon Vincent Laudone, Chief of Surgery.

He explains that surgical lights automatically adjust to eliminate shadows in the operating field and are temperature-adjusted to maintain accurate tissue color. Wide-screen, super-high-definition monitors are employed for laparoscopic and robotic surgery and can be used in all procedures to visually consult with onsite pathologists.

The operating rooms at the Josie Robertson Surgery Center feature state-of-the-art equipment incorporating the most-advanced technology available.”
—VINCENT LAUDONE

From left: Rebecca Twersky, Josie Robertson’s Chief of Anesthesia; and Vincent Laudone, Chief of Surgery.
Michelle Burke, Nursing Director of Perioperative Services, along with William Hoskins, recently retired as MSK’s Executive Director of Surgical Activities, launched a pilot program called Ambulatory Extended Recovery (AXR) to critically evaluate post-surgical recovery. AXR looked at surgical patients who currently had three-, four-, or five-day hospital stays and who might be moved to an ambulatory extended recovery program that would get them home in 24 hours or less.

“We focused on the surgical services we anticipated moving to the JRSC,” says Ms. Burke. “We began with breast, plastic surgery, and some head and neck surgeries. Then we determined that gynecologic and urologic surgeries, with their laparoscopic and robotic techniques, could also lend themselves well to this effort.”

The AXR pilot began on several Memorial Hospital inpatient units. “We developed criteria for patients we felt we could accept into the program,” says Ms. Burke. “We looked for people who did not have a lot of comorbidities, such as heart disease, that might preclude them from being in the program. We also assessed social support: Did a patient have someone at home who could care for them after the operation? For those patients we felt would do well, we developed a different methodology for caring for and educating them.”

This included putting patients on a track requiring them to achieve specific post-surgical milestones by certain times to see whether they could return home within 24 hours. Ms. Burke and her colleagues also developed a comprehensive home follow-up program. The pilot lasted approximately four years, when it began to transition over to the JRSC.
The structure of the nursing teams delivering care at the JRSC is different than what a patient or caregiver may encounter almost anywhere else. For example, the presurgical nurse personally escorts the patient to the operating room and introduces him or her to the OR nurse. “This adds a level of comfort because the patient has already developed a relationship with that nurse,” explains clinical nurse IV Amy Pippin, who has worked at MSK for ten years.

Cross-Training — and We Don’t Mean the Gym

Another enhancement in JRSC nursing is what’s known as cross-training. All perianesthesia nurses are trained in both preoperative and postoperative patient care. “Every JRSC nurse has knowledge and skills to work preop, postop, and extended stay, which offers more flexibility for staffing because nurses are able to practice in any area of the facility as needed,” says Ms. Pippin. “Each nurse understands the entire process from beginning to end.”

Cross-trained nurses also benefit patients in other ways. Each nurse is able to anticipate her or his patients’ needs at any point during their stay. Patients can feel secure in that knowledge, and it also reduces anxiety for waiting family members. In certain cases, it may even be possible for a patient to have the same nurse before and after surgery.

In another innovation, patients are moved to one room to recover comfortably after surgery, rather than first having to go to a recovery room — also called a post-anesthesia care unit — and then being transported to yet another room once they’re awake. Not moving a patient more than once after surgery makes for a better, more comfortable experience, is more efficient, and reduces the potential for errors from handoffs of care from one team to another.

Our hope is that patients and caregivers have a warm feeling that we’re at Josie to dedicate all our time and attention to them.”

—MARCIA LEVINE

It’s All about the Patient

While there are many new processes in place at the JRSC, the quality of nursing care is the same high quality as patients experience in Memorial Hospital. “We all share the same values, beliefs, and ethics and take a team approach to looking after our patients,” says clinical nurse IV Tamara Strah, who has worked at MSK for 14 years and was previously an OR nurse in MSK’s Surgical Day Hospital. “We already have the culture. We’re just bringing it to the JRSC.”

“Our hope is that patients and caregivers have a warm feeling that we’re at Josie to dedicate all our time and attention to them,” concludes Marcia Levine, Nursing Director of Perioperative Services at Josie Robertson. “Everyone at the JRSC plays an integral role in patient care — providing feedback, measuring progress, and offering ideas about how to continuously improve our quality of care and patient outcomes.”
# Statistical Profile

## Patient Care

<table>
<thead>
<tr>
<th></th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Admissions: Adults</td>
<td>22,983</td>
<td>23,139</td>
<td>20,773</td>
<td>20,640</td>
<td>21,064</td>
</tr>
<tr>
<td>Patient Admissions: Children</td>
<td>1,503</td>
<td>1,459</td>
<td>1,553</td>
<td>1,504</td>
<td>1,403</td>
</tr>
<tr>
<td>Total Admissions</td>
<td>24,486</td>
<td>24,598</td>
<td>22,326</td>
<td>22,144</td>
<td>22,467</td>
</tr>
<tr>
<td>Total Patient Days</td>
<td>140,990</td>
<td>149,368</td>
<td>144,345</td>
<td>146,855</td>
<td>151,827</td>
</tr>
<tr>
<td>Average Patient Stay (days)</td>
<td>5.8</td>
<td>6.1</td>
<td>6.5</td>
<td>6.6</td>
<td>6.8</td>
</tr>
<tr>
<td>Bed Occupancy Rate (1)</td>
<td>82.2%</td>
<td>87.0%</td>
<td>83.0%</td>
<td>84.3%</td>
<td>90.9%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outpatient MD Visits: Manhattan</td>
<td>432,802</td>
<td>436,510</td>
<td>463,724</td>
<td>480,260</td>
<td>489,897</td>
</tr>
<tr>
<td>Outpatient MD Visits: Regional Network</td>
<td>103,098</td>
<td>104,964</td>
<td>108,198</td>
<td>113,699</td>
<td>136,506</td>
</tr>
<tr>
<td>Total Outpatient Visits</td>
<td>535,900</td>
<td>541,474</td>
<td>571,922</td>
<td>593,959</td>
<td>626,403</td>
</tr>
<tr>
<td>Screening Visits</td>
<td>20,518</td>
<td>15,519</td>
<td>12,826</td>
<td>10,282</td>
<td>22,403</td>
</tr>
<tr>
<td>Surgical Cases</td>
<td>19,374</td>
<td>19,691</td>
<td>20,465</td>
<td>20,420</td>
<td>21,368</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiation Treatments and Implants: Manhattan</td>
<td>60,393</td>
<td>60,289</td>
<td>61,335</td>
<td>62,375</td>
<td>60,804</td>
</tr>
<tr>
<td>Radiation Treatments and Implants: Network</td>
<td>51,615</td>
<td>50,476</td>
<td>53,660</td>
<td>55,229</td>
<td>58,041</td>
</tr>
<tr>
<td>Total Radiation Treatments and Implants</td>
<td>112,008</td>
<td>110,765</td>
<td>114,995</td>
<td>117,604</td>
<td>118,845</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic and Interventional Radiology Procedures</td>
<td>377,360</td>
<td>391,187</td>
<td>416,360</td>
<td>435,501</td>
<td>466,848</td>
</tr>
<tr>
<td>Clinical Investigation Protocols (2)</td>
<td>552</td>
<td>657</td>
<td>735</td>
<td>776</td>
<td>879</td>
</tr>
</tbody>
</table>

(1) Based on adjusted bed count  
(2) Excludes studies closed to accrual
### Staff

<table>
<thead>
<tr>
<th>Category</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sloan Kettering Institute Members</td>
<td>143</td>
<td>149</td>
<td>143</td>
<td>140</td>
<td>140</td>
</tr>
<tr>
<td>Hospital Attending Staff</td>
<td>834</td>
<td>876</td>
<td>935</td>
<td>995</td>
<td>1,033</td>
</tr>
<tr>
<td>Registered Nurses</td>
<td>2,018</td>
<td>2,133</td>
<td>2,221</td>
<td>2,373</td>
<td>2,605</td>
</tr>
<tr>
<td>Administrative and Support Staff</td>
<td>8,989</td>
<td>9,281</td>
<td>9,707</td>
<td>10,223</td>
<td>10,965</td>
</tr>
<tr>
<td>Total Staff*</td>
<td>11,950</td>
<td>12,402</td>
<td>12,975</td>
<td>13,699</td>
<td>14,711</td>
</tr>
<tr>
<td>Volunteers</td>
<td>1,058</td>
<td>1,018</td>
<td>1,004</td>
<td>902</td>
<td>967</td>
</tr>
</tbody>
</table>

*In 2015, 32 staff members held appointments in both the Institute and the Hospital.

### Education

<table>
<thead>
<tr>
<th>Category</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Residents and Clinical Fellows — Positions</td>
<td>440</td>
<td>445</td>
<td>464</td>
<td>465</td>
<td>464</td>
</tr>
<tr>
<td>Residents and Clinical Fellows — Annual Total</td>
<td>1,676</td>
<td>1,682</td>
<td>1,691</td>
<td>1,674</td>
<td>1,723</td>
</tr>
<tr>
<td>Research Fellows</td>
<td>321</td>
<td>320</td>
<td>323</td>
<td>351</td>
<td>355</td>
</tr>
<tr>
<td>Research Scholars</td>
<td>131</td>
<td>124</td>
<td>133</td>
<td>110</td>
<td>98</td>
</tr>
<tr>
<td>Research Associates</td>
<td>82</td>
<td>89</td>
<td>91</td>
<td>95</td>
<td>110</td>
</tr>
<tr>
<td>Graduate Research Assistants</td>
<td>29</td>
<td>39</td>
<td>41</td>
<td>47</td>
<td>47</td>
</tr>
<tr>
<td>PhD Candidates</td>
<td>225</td>
<td>222</td>
<td>227</td>
<td>239</td>
<td>265</td>
</tr>
<tr>
<td>MD/PhD Candidates</td>
<td>21</td>
<td>21</td>
<td>19</td>
<td>18</td>
<td>20</td>
</tr>
<tr>
<td>Registrants in CME Programs</td>
<td>2,533</td>
<td>3,968</td>
<td>3,681</td>
<td>5,614</td>
<td>3,581</td>
</tr>
<tr>
<td>Medical Observers</td>
<td>526</td>
<td>566</td>
<td>630</td>
<td>579</td>
<td>574</td>
</tr>
<tr>
<td>Medical Students</td>
<td>419</td>
<td>431</td>
<td>392</td>
<td>505</td>
<td>548</td>
</tr>
<tr>
<td>Nursing Students</td>
<td>142</td>
<td>178</td>
<td>179</td>
<td>257</td>
<td>312</td>
</tr>
<tr>
<td>Social Work Students</td>
<td>6</td>
<td>6</td>
<td>7</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>Radiation Oncology Technology Students</td>
<td>14</td>
<td>13</td>
<td>15</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>Physical Therapy Students</td>
<td>4</td>
<td>7</td>
<td>2</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Occupational Therapy Students</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>3</td>
<td>2</td>
</tr>
</tbody>
</table>
Financial Summary

2015 Total Operating Revenues

$3,675,485

$2,809,813
Patient Care Revenue

$432,287
Grants, Contracts, and Royalties

$267,066
Contributions and Pledge Payments

$166,319
Other Income

2015 Total Operating Expenses

$3,506,316

$1,987,388
Compensation and Fringe Benefits

$1,172,467
Purchased Supplies and Services

$232,866
Depreciation and Amortization

$113,595
Other Expenses
### Operating Revenues (in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Care Revenue</td>
<td>$2,141,421</td>
<td>$2,201,941</td>
<td>$2,367,731</td>
<td>$2,560,457</td>
<td>$2,809,813</td>
</tr>
<tr>
<td>Grants and Contracts</td>
<td>$190,948</td>
<td>$185,160</td>
<td>$202,061</td>
<td>$229,562</td>
<td>$234,402</td>
</tr>
<tr>
<td>Contributions</td>
<td>$128,354</td>
<td>$128,253</td>
<td>$138,343</td>
<td>$168,797</td>
<td>$137,538</td>
</tr>
<tr>
<td>Net Assets Released from Restrictions — Pledge Payments</td>
<td>$64,798</td>
<td>$86,820</td>
<td>$79,199</td>
<td>$103,112</td>
<td>$129,528</td>
</tr>
<tr>
<td>Royalty Income</td>
<td>$77,510</td>
<td>$78,350</td>
<td>$94,058</td>
<td>$162,710</td>
<td>$197,885</td>
</tr>
<tr>
<td>Other Income</td>
<td>$48,351</td>
<td>$51,167</td>
<td>$57,150</td>
<td>$62,643</td>
<td>$66,032</td>
</tr>
<tr>
<td>Unrestricted Investment Return Allocated to Operations</td>
<td>$104,699</td>
<td>$75,877</td>
<td>$82,028</td>
<td>$87,917</td>
<td>$90,648</td>
</tr>
<tr>
<td>Transfer of Board-Designated Annual Royalty Annuitzation</td>
<td>$46,417</td>
<td>$51,709</td>
<td>$57,495</td>
<td>$15,885</td>
<td>$9,639</td>
</tr>
<tr>
<td><strong>Total Operating Revenues</strong></td>
<td><strong>$2,802,498</strong></td>
<td><strong>$2,859,277</strong></td>
<td><strong>$3,078,065</strong></td>
<td><strong>$3,391,083</strong></td>
<td><strong>$3,675,485</strong></td>
</tr>
</tbody>
</table>

### Operating Expenses (in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compensation and Fringe Benefits</td>
<td>$1,466,667</td>
<td>$1,582,212</td>
<td>$1,689,501</td>
<td>$1,782,477</td>
<td>$1,987,388</td>
</tr>
<tr>
<td>Purchased Supplies and Services</td>
<td>$835,621</td>
<td>$879,219</td>
<td>$924,691</td>
<td>$1,062,603</td>
<td>$1,172,467</td>
</tr>
<tr>
<td>Provision for Bad Debts and Assessments</td>
<td>$18,285</td>
<td>$17,541</td>
<td>$19,969</td>
<td>$35,859</td>
<td>$64,194</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>$195,461</td>
<td>$210,810</td>
<td>$210,373</td>
<td>$217,342</td>
<td>$232,866</td>
</tr>
<tr>
<td>Interest Expense</td>
<td>$57,098</td>
<td>$54,894</td>
<td>$55,039</td>
<td>$50,147</td>
<td>$49,401</td>
</tr>
<tr>
<td><strong>Total Operating Expenses</strong></td>
<td><strong>$2,573,132</strong></td>
<td><strong>$2,744,676</strong></td>
<td><strong>$2,899,573</strong></td>
<td><strong>$3,148,428</strong></td>
<td><strong>$3,506,316</strong></td>
</tr>
</tbody>
</table>

### Income from Operations

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$229,366</td>
<td>$114,601</td>
<td>$178,492</td>
<td>$242,655</td>
<td>$169,169</td>
</tr>
</tbody>
</table>

### Philanthropic Revenue

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$301,374</td>
<td>$231,159</td>
<td>$380,500</td>
<td>$376,533</td>
<td>$276,747</td>
</tr>
</tbody>
</table>

### Capital Spending

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$223,251</td>
<td>$258,613</td>
<td>$315,282</td>
<td>$473,859</td>
<td>$710,873</td>
</tr>
</tbody>
</table>

### Balance Sheet Summary

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assets</td>
<td>$6,790,005</td>
<td>7,795,606</td>
<td>8,481,418</td>
<td>8,963,268</td>
<td>9,592,021</td>
</tr>
<tr>
<td>Liabilities</td>
<td>2,848,843</td>
<td>3,562,546</td>
<td>3,337,444</td>
<td>3,596,860</td>
<td>4,058,058</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td><strong>$3,941,162</strong></td>
<td><strong>$4,233,060</strong></td>
<td><strong>$5,143,974</strong></td>
<td><strong>$5,366,408</strong></td>
<td><strong>$5,533,963</strong></td>
</tr>
</tbody>
</table>
Boards of Overseers and Managers

as of March 31, 2016

DOUGLAS A. WARNER III
Chair

JAMES D. ROBINSON III
Honorary Chair

MARIE-JOSÉE KRAVIS
Vice Chair of Boards
Chair, Board of Managers,
Sloan Kettering Institute

LOUIS V. GERSTNER, JR.
Honorary Chair of the Board,
Sloan Kettering Institute

SCOTT M. STUART
Vice Chair of Boards
Chair, Board of Managers,
Memorial Hospital

RICHARD I. BEATTIE
Honorary Chair of the Board,
Memorial Hospital

CLIFTON S. ROBBINS
Treasurer

NORMAN C. SELBY
Secretary

CRAIG B. THOMPSON, MD
President and Chief Executive Officer

DOMINIC BARTON
Richard I. Beattie
Mrs. Edwin M. Burke
Mrs. John J. Byrne
Mrs. Joseph A. Califano, Jr.
Ian M. Cook
Stanley F. Druckenmiller
Anthony B. Evnin, PhD
Roger W. Ferguson, Jr.
Henry A. Fernandez
Steve Forbes
William E. Ford
Richard N. Foster, PhD
Stephen Friedman

ELLLEN V. FUTTER
Philip H. Geier, Jr.
Laurie H. Glimcher, MD
Jonathan N. Graye
Bette-Anne Gwathmey
William B. Harrison, Jr.
Benjamin W. Heineman, Jr.
David H. Koch
Marie-Josée Kravis
Paul A. Marks, MD
Donald B. Marron
Kathryn Martin
Jamie C. Nicholls

JAMES G. NIVEN
Hutham S. Olayan
Bruce C. Ratner
Clifton S. Robbins
Alexander T. Robertson
James D. Robinson III
Virginia M. Rometty
David M. Rubenstein
Lewis A. Sanders
Norman C. Selby
Stephen C. Sherrill

DOMINIC BARTON
Richard I. Beattie
Mrs. Edwin M. Burke
Mrs. John J. Byrne
Mrs. Joseph A. Califano, Jr.
Ian M. Cook
Stanley F. Druckenmiller
Anthony B. Evnin, PhD
Roger W. Ferguson, Jr.
Henry A. Fernandez
Steve Forbes
William E. Ford
Richard N. Foster, PhD
Stephen Friedman

DOMINIC BARTON
Richard I. Beattie
Mrs. Edwin M. Burke
Mrs. John J. Byrne
Mrs. Joseph A. Califano, Jr.
Ian M. Cook
Stanley F. Druckenmiller
Anthony B. Evnin, PhD
Roger W. Ferguson, Jr.
Henry A. Fernandez
Steve Forbes
William E. Ford
Richard N. Foster, PhD
Stephen Friedman

* ex officio

BOARD OF OVERSEEERS EMERITI

Peter O. Crisp
Richard M. Furlaud
James W. Kinnear
Elizabeth J. McCormack, PhD
Benjamin M. Rosen
Jack Rudin
Fayez S. Sarofim
Mrs. Arnold Schwartz

BOARD OF SCIENTIFIC CONSULTANTS

Frederick R. Applebaum, MD
James R. Downing, MD
Caryn Lerman, PhD
Gregory L. Verdine, PhD
Richard Axel, MD
Levi A. Garraway, MD, PhD
Arthur Levinson, PhD
Ralph Weissleder, MD, PhD
Philip A. Cole, MD, PhD
Maura L. Gillison, MD, PhD
Paul Nurse, PhD
Irving L. Weissman, MD
Nancy E. Davidson, MD
Joseph L. Goldstein, MD
Stanley R. Riddell, MD
James E. Rothman, PhD
Titia de Lange, PhD
Gregory Hannon, PhD

+ ex officio
Leadership
Memorial Sloan Kettering Cancer Center

as of March 31, 2016

PAUL A. MARKS, MD
President Emeritus

CRAIG B. THOMPSON, MD
President and Chief Executive Officer

KATHRYN MARTIN
Chief Operating Officer

JOSÉ BASELGA, MD, PhD
Physician-in-Chief and
Chief Medical Officer, Memorial Hospital

JOAN MASSAGUÉ, PhD
Director, Sloan Kettering Institute

ELIZABETH N. MCCORMICK, MSN, RN, CENP
Senior Vice President and Chief Nursing Officer

LARRY NORTON, MD
Deputy Physician-in-Chief, Breast
Cancer Programs and Medical Director,
Evelyn H. Lauder Breast Center

PETER STETSON, MD, MA
Deputy Physician-in-Chief and
Chief Health Informatics Officer

RICHARD R. BARAKAT, MD
Deputy Physician-in-Chief,
Regional Care Network and
MSK Cancer Alliance

PAUL SABBATINI, MD
Deputy Physician-in-Chief, Clinical Research

MURRAY F. BRENNA, MD
Senior Vice President, International Programs and
Director, International Center

KERRY BESSEY
Senior Vice President and
Chief Human Resources Officer

KENT SEPKOWITZ, MD
Deputy Physician-in-Chief, Quality and Safety

JASON KLEIN
Senior Vice President and
Chief Investment Officer

PAUL NELSON
Senior Vice President,
Financial Planning

MARGARET M. BURKE
Senior Vice President,
Ambulatory Care and Hospital Operations

RUTH LANDE
Senior Vice President, Patient Revenues

ROGER N. PARKER, ESQ.
Executive Vice President and
General Counsel

ERIC COTTINGTON, PhD
Senior Vice President, Research and
Technology Management

CAROLYN B. LEVINE, ESQ.
Deputy General Counsel and
Corporate Secretary

WENDY PERCHICK
Senior Vice President,
Strategic Planning and Innovation

NED GROVES
Executive Vice President and
Hospital Administrator

EDWARD J. MAHONEY
Senior Vice President,
Facilities Management and Construction

PATRICK A. SKARULIS
Senior Vice President and
Chief Information Officer

MICHAEL P. GUTNICK
Executive Vice President and
Chief Financial Officer

CYNTHIA MCCOLLUM
Senior Vice President,
Hospital Administration

CAROL A. SLATTERY
Vice President,
Sloan Kettering Institute Administration

JAMES T. HARDEN
Senior Vice President,
Strategic Partnerships

ANNE MC SWEENEY
Special Advisor to the President,
Development

MARK SVENNINGSON
Senior Vice President,
Finance and Controller

ELIZABETH A. HERBERT
Senior Vice President,
Hospital Administration

AVICE A. MEEHAN
Senior Vice President and
Chief Communications Officer

EDWIN TALIAFERO
Vice President,
Internal Audit and Compliance and
Chief Compliance Officer

PAUL A. MARKS, MD
President Emeritus
LOUIS V. GERSTNER, JR.
Chairman of the Board

CRAIG B. THOMPSON, MD
President

JOAN MASSAGUÉ, PhD
Provost

KENNETH J. MARIANS, PhD
Dean

LINDA D. BURNLEY
Associate Dean

KATHRYN MARTIN
Treasurer

MARK SVENNINGSON
Assistant Treasurer

CAROLYN B. LEVINE, ESQ.
Secretary

TRUSTEES

Richard I. Beattie
Ellen V. Futter
Louis V. Gerstner, Jr.
Laurie H. Glimcher, MD

David H. Koch
Marie-Josée Kravis
Craig B. Thompson, MD
Douglas A. Warner III

LOUIS V. GERSTNER, JR. Graduate School of Biomedical Sciences
Memorial Sloan Kettering Cancer Center
as of March 31, 2016

Sloan Kettering Division
Weill Cornell Graduate School of Medical Sciences
as of March 31, 2016

JOAN MASSAGUÉ, PhD
Director

KENNETH J. MARIANS, PhD
Director, Graduate Studies

GRADUATE PROGRAM CO-CHAIRS

NIKOLA P. PAVLETICH, PhD
Biochemistry and Structural Biology Unit

DAVID A. SCHEINBERG, MD, PhD
Pharmacology Unit

ANDREW KOFF, PhD
Molecular Biology Unit

ALEXANDER Y. RUDENSKY, PhD
Immunology and Microbial Pathogenesis Unit

MARILYN D. RESH, PhD
Cell and Developmental Biology Unit
As it enters its final year, the Campaign for Memorial Sloan Kettering has maintained its strong forward momentum, with nearly 1 million gifts received in 2015. As of December 31, the Campaign had recorded a total of $3.83 billion in gifts and pledges, putting it $333 million above its goal of $3.5 billion. The Campaign is on track to pass the $4 billion mark by the time it concludes at the end of 2016.

A record-setting $96.2 million in cash receipts for the month of December brought the year to a resounding close. It was the Campaign’s second consecutive record-setting December.

Key to such strong ongoing achievement are the farsighted donors who have been so consistently generous in support of MSK and its mission. Special recognition is also due to the leadership provided by the Campaign’s co-chairs, Douglas A. Warner III and Louis V. Gerstner, Jr., who have guided the historic fundraising effort from its earliest days. Through their work with potential donors, as well as in their collaborative efforts with MSK President and CEO Craig B. Thompson and their colleagues on the Board, they have helped to ensure that the Campaign embodies MSK’s highest aspirations even as it generates the funds needed to meet top institutional priorities.

During the course of the Campaign, MSK has built one of the nation’s most productive and highly efficient fundraising operations. Under the direction of Anne M. McSweeney and Richard K. Naum, MSK’s Development Office now has in place the solid foundations required for long-term fundraising success.

Of the many contributions received in 2015, several stood out as exemplifying the spirit of thoughtful generosity that inspires donors at every level. These include a commitment of $35 million from the Parker Institute for Cancer Immunotherapy; a pledge of $15 million from Board member David M. Rubenstein in support of the David M. Rubenstein Center for Pancreatic Cancer Research, which brings his total support for the initiative to $25 million; $10 million from Robert and Kate Niehaus to create the Robert and Kate Niehaus Center for Inherited Cancer Genomics; a commitment of $5 million from Nassef Sawiris to establish the Sawiris Family Initiative in Blood Cancer Research; and $5 million from the Debra and Leon Black Family Foundation for the Acral Melanoma Initiative.

Memorial Sloan Kettering also benefited enormously from the thousands of volunteers who put their energy and enthusiasm to work for the institution by participating in athletic fundraising events. Nearly 950 runners ran in the 2015 TCS New York City Marathon as members of Fred’s Team, raising a total of more than $5.3 million for research. And Cycle for Survival continued to grow at a rapid pace, with 21,000 cyclers taking part in events across the nation in 2015. In its first nine years, Cycle for Survival raised $76.5 million and supported more than 100 clinical trials and research studies focused on rare cancers.

The Campaign for Memorial Sloan Kettering has spanned a critical period in the fight against cancer, one marked by exciting scientific breakthroughs and innovative approaches to treatment. Fueled by the support of thousands of benefactors, MSK’s physicians and scientists are intensifying their efforts on every front, making a real difference in the lives of patients and paving the way to even greater future progress.
### Donors to the Campaign for Memorial Sloan Kettering

#### $200,000,000 AND ABOVE
- **David H. Koch**

#### $100,000,000 — $199,999,999
- **The Estate of Geoffrey Beene**
- **Henry and Marie-Josée Kravis**
- **The Starr Foundation**
- **Mortimer B. Zuckerman**

#### $50,000,000 — $99,999,999
- **Stanley F. and Fiona Druckenmiller**
- **Mr. and Mrs. William H. Goodwin, Jr., and the Commonwealth Foundation for Cancer Research**
- **The Leonard and Evelyn Lauder Foundation**
- **Virginia and D. K. Ludwig Fund for Cancer Research**

#### $25,000,000 — $49,999,999
- **The Atlantic Philanthropies**
- **The Breast Cancer Research Foundation**
- **Jack and Dorothy Byrne Foundation**
- **The Louis V. Gerstner, Jr. Foundation, Inc.**
- **The Sidney Kimmel Foundation**
- **Parker Institute for Cancer Immunotherapy**
- **Prostate Cancer Foundation**

#### $20,000,000 — $24,999,999
- **Anonymous**
- **The Society of MSK**

#### $10,000,000 — $19,999,999
- **Anonymous**
- **Bristol-Myers Squibb Company**
- **Trust of Burton Abrams**
- **The Elmer and Mamdouha Bobst Foundation**
- **Mr. and Mrs. Raymond T. Dalio**
- **The Stephen and Barbara Friedman Foundation**
- **Alan and Sandra Gerry**
- **The Arnold and Arlene Goldstein Family Foundation**

#### $5,000,000 — $9,999,999
- **Anonymous**
- **Band of Parents Foundation**
- **Robert and John Bendheim**
- **The Leon Black Family Foundation, Inc.**
- **The Carson Family Charitable Trust**
- **The Steven A. and Alexandra M. Cohen Foundation, Inc.**
- **Trust of Richard J. Eiseman**
- **Mr. and Mrs. Philip H. Geier, Jr.**
- **Estate of Sherlock Hibbs**
- **ICAP**
- **Dr. and Mrs. Min-Hwan Kao**
- **F. M. Kirby Foundation, Inc.**
- **The Robert J. Kleberg, Jr., and Helen C. Kleberg Foundation**
- **Trust of L. H. P. Klotz**
- **John W. Kluge**
- **Trust of Evelyn Lauder**
- **The Levensfeld Foundation**
- **Estate of Tse Kyung Lee**
- **The Leon Lowenstein Foundation, Inc., and Robert and John Bendheim**
- **The Lustgarten Foundation for Pancreatic Research**
- **Martin S. and Sheila Major and Family**
- **Melanoma Research Alliance**
- **Estate of Samuel U. Mitchell**
- **Jamie Nicholls and Fran Biondi Charitable Trust**
- **Peserga International Foundation**

#### $2,500,000 — $4,999,999
- **Anonymous**
- **Mr. and Mrs. Bruce Adam**
- **The Allbritton Foundation**
- **Bethany Allen**
- **Stephen and Madeline Anbinder**
- **John M. Angelo and Judy Hart Angelo**
- **The Laura and John Arnold Foundation**
- **Estate of Eleanor Backer**
- **The Arthur & Rochelle Belfer Foundation**
- **Estate of Mary Ann Benjamin**
- **Estate of Lilian R. Berkman**
- **Mr. and Mrs. Melvin R. Berlin Family**
- **The James E. and Diane W. Burke Foundation, Inc.**
- **Estate of Nizza Burstyn**
- **Mrs. D. Wayne Calloway**
- **Iris and B. Gerald Cantor Foundation**
- **The Kristen Ann Carr Fund**
- **Estate of Marion B. Carstairs**
- **James D. Carter**
- **Estate of Franklin Chenenky**
- **Pei-Yuan Chia and the Chia Family Foundation**
- **Charles Payson Coleman**
- **Ian and Patricia Cook**
- **Crimson Lion / Lavine Family Foundation**
- **The Irma L. and Abram S. Croll Charitable Trust**
Donors to the Campaign for Memorial Sloan Kettering

The Decathlon
The Doris Duke Charitable Foundation
The Mitzi and Warren Eisenberg Foundation/
  The Susan and Leonard Feinstein
  Foundation
Anthony B. and Judith W. Evnin
Farmer Family Foundation
Estate of Elizabeth M. Frelinghuysen
Estate of Jeanette R. Fulham
Goldman Sachs & Company
Estate of Francis Gonzalez
The Gray Foundation - Bassett Initiative
Mr. and Mrs. Jonathan N. Grayer
Hazen Polsky Foundation, Inc.
William Randolph Hearst Foundations
Mr. and Mrs. Benjamin W. Heineman, Jr.
Estate of Irma A. Howard
William Lawrence & Blanche Hughes Foundation
The Jewish Communal Fund
W. M. Keck Foundation
Estate of Martin C. Kessler
Kids Walk for Kids with Cancer
Susan G. Komen for the Cure
Myra Nelson Larrison
Livestrong Foundation
The Lymphoma Foundation
Trust of Philip R. Mallory
The Maloris Foundation
Trust of Estelle A. Manning
The T. J. Martell Foundation for Leukemia, Cancer and AIDS Research
The G. Harold & Leila Mathers Foundation
Estate of Charles J. Mauro
The Abby R. Mauzé Charitable Trust
Estate of Florence Miner
Gloria Miner
The Naddisy Foundation
The New York Community Trust
The Samuel I. Newhouse Foundation
Stayros Niarchos Foundation
Nonna’s Garden Foundation
Ronald O. Perelman
Estate of Catherine R. Price
Laura and Christopher A. Pucillo
The Jim and Linda Robinson Foundation
Jack Rudin
The Louis & Rachel Rudin Foundation
The May & Samuel Rudin Family Foundation
Estate of Marilyn L. Schaefer
Richard Serra and Clara Weyergraf-Serra
Estate of Grace A. Shapiro
Mr. and Mrs. H. Virgil Sherrill
The Joachim Silberman Family
Paul E. Singer
Joan and Joel Smilow
The Sontag Foundation
Sportsmen for Charity
George Strawbridge, Jr.

The Margaret Dorrance Strawbridge Foundation of Pennsylvania I
Mr. and Mrs. Scott Stuart
The Joseph and Arlene Taub Foundation
Margaretta J. Taylor
Estate of Richmond E. Thompson
Trust of Jane Toplitt
TOSA Foundation
The V Foundation for Cancer Research
Trust of Bessie Weintraub

$1,000,000 — $2,499,999

Mr. and Mrs. Andrew B. Abramson
Mr. and Mrs. Frederick R. Adler
Alex’s Lemonade Stand Foundation
Mr. and Mrs. Fred M. Alger III
Allen & Company, Inc.
Estate of Billie H. Allen
Alliance for Cancer Gene Therapy
Anonymous
Estate of Boone P. Arledge
The Award of Courage Corporation
Roger and Lori Bahnik
Estate of Eileen W. Bamberger
The Batishwa Fellowship
Trust of Edgar D. Baumgartner
Mr. and Mrs. Daniel C. Benton
Estate of Irma Berg
Allen and Joan Bildner
The Anita and Leonard Boxer Family Foundation
Breast Cancer Alliance, Inc.
Mr. and Mrs. Viatcheslav I. Brecht
Peter and Linda Bren
The Andrea and Charles Bronfman Philanthropies, Inc.
Estate of Helen Brown
Trust of Emil A. Buelens
Tory Burch
Estate of Diane B. Burkhart
The Burnett Foundation
Burroughs Wellcome Fund
Cancer Research Institute
Robert B. Catell
John and Michael Chandris
The Laura Chang and Arnold Chavkin Charitable Fund
Trust of Paul H. Chook
Trust of Charles P. Ciaffone
Trust of George Clegg
Simon & Eve Colin Foundation, Inc.
The Comer Science and Education Foundation
The Connecticut Sports Foundation
Cookies for Kids’ Cancer
Trust of James J. Corbalis, Jr.
Sharon Levine Corzine
Trust of Caroline S. Coulton

The Countess Moira Foundation
Mr. and Mrs. Peter O. Crisp
Cure Breast Cancer Foundation, Inc.
Estate of Helen M. Curry
Trust of Margaret E. Dahm
John and Georgia DallePezze
Dennis D. Dammerman
The Dana Foundation
Mr. and Mrs. Marvin H. Davidson
Trust of Myra Davis
Estate of Bernard S. Davison
Christina and Emmanuel Di Donna
Estate of Charles E. Dillman
Gloria DiPietro-Cooper
Michael Douglas and Catherine Zeta-Jones
Trust of Nancy K. Dunn
The Ellison Medical Foundation
The Emerald Foundation
Mr. and Mrs. Israel Englander
Entertainment Industry Foundation
Estate of Selma Ettenberg
The Eunice Foundation
Estate of Harry Fagen
Trust of Harold Farrington
The John K. Figge Family
Estate of Barbara D. Finberg
The Jerome and Anne C. Fisher Charitable Foundation
Flight Attendant Medical Research Institute
The Stephanie and Lawrence Flinn, Jr. Charitable Trust
The Raymond and Maria Floyd Family Foundation
Estate of Harry N. Forman
Lorraine Friedman
Trust of Oscar H. Friedman
Friezo Family Foundation
Fund for Ophthalmic Knowledge
Estate of Frank H. Gabriel
Gabrielle’s Angel Foundation
Sara Gadd
Estate of Thomas Gardiner
Trust of Virginia L. Garrison
Trust of Florence K. Geffen
The Lawrence M. Gelb Foundation, Inc.
Richard L. Gelb
Genentech
General Electric Company
Eileen Genet Fund for Ovarian Cancer Research and Prevention
Trust of Josephine A. Gilmore
Estate of Thelma Gish
GIST Cancer Awareness Foundation
GIST Cancer Research Fund
Estate of Anna H. Gleason
Miriam and Alan Goldberg
The Joyce & Irving Goldman Family Foundation
The Horace W. Goldsmith Foundation
Donors to the Campaign for Memorial Sloan Kettering

Mr. and Mrs. Joel Mallah
Mr. and Mrs. J. Randall MacDonald
Lymphoma Research Foundation
Robert S. Ludwig and Gwenyth E. Rankin
Carol and Michael Lowenstein
The Litwin Foundation
The LisaBeth Foundation
The Litwin Foundation
Carol and Michael Lowenstein
Robert S. Ludwig and Gwenyth E. Rankin
Lymphoma Research Foundation
Mr. and Mrs. J. Randall MacDonald
Mr. and Mrs. Joel Mallah

The Lois H. Mann Charitable Foundation
Margaux's Miracle Foundation
Mrs. Joseph L. Martino
Mrs. William L. Matheson
Nancy and Paul McCartney
Mr. and Mrs. Thomas E. McInerney
Estate of Donald G. McKeon
Merrill Lynch & Co. Foundation, Inc.
Fred and Marie-Noelle Meyer
Estate of Wilma S. Mills
Jim and Mary Jane Milton
Julie and Edward J. Minskoff
Estate of Robert C. Mitchell
Trust of Douglas C. Mohl
The Ambrose Monell Foundation
Tom and Janet Montag
Estate of Warren A. Montel
Morgan Stanley
The William T. Morris Foundation
Trust of Anna V. Muller
Estate of Elaine Muller
Mushett Family Foundation, Inc.
Trust of Saul Nathanson
Needles' Family Charitable Lead Trust
The New York Yankees Foundation
The Olayan Group
Pancreatic Cancer Action Network
Francine Parnes
Pediatric Cancer Foundation
Estate of Frederick Pelda
John and Francie Pepper
Trust of Elizabeth L. Perkins
Perry Capital LLC
Pershing Square Sohn Cancer Research Alliance
Estate of Jeanne Poli
Bernard Posner
RJR Oncodermatology Fund
Sara and Iser Rabinovitz
Mrs. Katharine J. Rayner
Revlon
Charles H. Revson Foundation
Estate of Edith Roberts
Estate of Josephine T. Robertson
Estate of Anne Morales Rodgers
Mary Jo and Brian Rogers
The Felix and Elizabeth Rohatyn Foundation
The Laura Rosenberg Foundation, Inc.
Estate of Lillian E. Rosenmerkel
Juliet Rosenthal Foundation
The Peter M. Sacerdote Foundation
Lewis A. Sanders
Fayez Sarofim & Co.
Estate of Margaret W. Schafer
Estate of Catherine M. Schooley
The Beatrice & Samuel A. Seaver Foundation
Mr. and Mrs. Norman C. Selby
Dr. David E. and Beth Kobliner Shaw
The Shen Family Foundation
Trust of Henry H. Shepard
Trust of William and Isabelle Sherlock
Mr. and Mrs. Stephen C. Sherrill
Alfred J. and Stephanie Shuman through the Windmill Lane Foundation
Mr. and Mrs. Herbert J. Siegel
M. Steven and S. David Silbermann
The Rosanne H. Silbermann Foundation
Mary Ann and Arthur M. Siskind through the Siskind Family Sarcoma Fund
The Skirball Foundation
Estate of Ann Smith
Trust of William Kirkland Smith
Trust of Emily V. Smyth
Trust of Clemance and Edwin Snyder
Ira Sohn Conference Foundation, Inc.
Susan and Peter Solomon Family Foundation
St. Baldrick's Foundation
John R. & Inge P. Stafford Foundation
Estate of Stanley R. Stones
Mr. and Mrs. David K. Storrs
Mr. and Mrs. Paul A. Street
The Sussman Family Fund
Trust of M. Allen Swift
Tang Family Foundation
Tarnopol Family Foundation
Terry Fox Run for Cancer Research (NYC)
Trust of Irving Tirkfield
Estate of Lillian Tomek
The Beth C. Tortolani Foundation
Dom and Tia Tran
Anthony and Carole Trapani
The Trump Group
Tudor Investment Corporation
Daniel P. and Grace I. Tully Foundation
Mr. and Mrs. Thomas Tuttle
Uniting Against Lung Cancer
Universal Network Television
Trust of Virginia and Edward Van Dalson
Vanguard Charitable Endowment Fund
Estate of William N. Vaughan
Trust of Edward W. Vollintine
Trust of Paul H. Volpe
Lucy R. Waletzky, MD
Joan and Sanford I. Weill
Louis and Jane Weinstock
The Lillian S. Wells Foundation, Inc.
Mr. and Mrs. Clay T. Whitehead
Estate of Carolyn H. Wilson
Winterburn Foundation
Diana S. Wister
The Meryl and Charles Witmer Charitable Foundation
Estate of Paul H. Volpe
Ziff Brothers Investment, LLC
Donors to the Campaign for Memorial Sloan Kettering

$500,000 — $999,999
Estate of Marguerite Abrams
AKTIV Foundation
The Rita Allen Foundation
American Brain Tumor Association
The American Italian Cancer Foundation
American Skin Association
Estate of Hugo Andriese
Anonymous
Arms Wide Open Childhood Cancer Foundation
Roland Arthur
Aventis Pharmaceuticals, Inc.
Mr. and Mrs. Robert C. Baker Family Foundation
Trust of Barbara G. Bargar
Estate of Doris A. Baumann
Richard I. Beattie
The Arnold and Mabel Beckman Foundation
Estate of Leola E. Bell
Trust of William T. Benitt
The Besen Family
The Bie Family Foundation
Estate of Dan Biele
Jane and Bill Bird
Trust of Susan E. Black
Betty, James, and Thomas Blake (The Thomas Blake, Sr. Memorial Fund)
The Blue Dot Foundation
Trust of Ethelvida Boehme
Estate of William Boehme
Mr. and Mrs. David Boies
Estate of Marcel S. Boilag
Trust of Frederick W. Bonacker, Jr.
The Bondi Foundation
Estate of Adele Bozio
Trust of Nancy J. Bradford
Terri Brodeur Breast Cancer Foundation
Trust of Dorothy Fielder Brown
The Honorable Tina Brozman Foundation
Mrs. Edwin M. Burke
Hilary and Joseph A. Califano, Jr.
The Cancer Research Foundation of America
The Richard E. Capri Foundation on behalf of the Wolf Family
Estate of Richard B. Carman
Mr. and Mrs. Kenneth Carmel
Estate of Wesley S. Carrick
The Tina and Richard V. Carolan Foundation
James & Patricia Cayne Charitable Trust
The Y. C. Ho/Helen and Michael Chiang Foundation
Trust of Betty R. Ciaffone
Citigroup
The Julie and Frank Cohen Foundation
Estate of Harry J. Colish
The Julien Collot Foundation, Inc.
Constant Convocation Center
The Elaine Terner Cooper Foundation
Trust of Fay copeland
Estate of Howard Corlies
Estate of Leonard Corso
Chandler Cox Foundation
Estate of Helen M. Cramer
CURE Childhood Cancer
CureSearch for Children’s Cancer
Mr. and Mrs. Rafic Dahan
Davis Charitable Foundation
Estate of Sandra Newman Dawson
The Thompson Dean Family Foundation
Estate of Carol T. Decker
The DeGroot Family Foundation
Annette and Oscar de la Renta
Dempster Charitable Trust
Deutsche Bank Securities Inc.
Trust of James Douglas
The Walter S. and Lucienne B. Driskill Foundation
Estate of Louis Duenneg
Trust of Phyllis K. Dunn
Mr. and Mrs. David Epstein
Equinox Holdings, Inc.
Edward P. Evans Foundation
Trust of Virginia J. Faber
Arthur Falcone
Estate of Katie Fasel
Estate of Beatrice Feinstein
Paul Felzen
The Fibrolamellar Cancer Foundation
Estate of Alice H. Ficht
Trust of Alice D. Fiedler
Trust of Marie Finch
The Grace J. Fippinger Foundation, Inc.
Estate of Susan L. Fischer
The Michael J. Fox Foundation
Trust of Ira S. French
Trust of Dr. Benjamin T. Friedman
Trust of Edith West Friedman
Estate of Maud Gallagher
The Gateway for Cancer Research
Estate of Joseph G. Gaumont
Estate of Selma Geller
Joe Gellert
Estate of Lillian B. George
The Gerber Foundation
The Aaron and Betty Gilman Family Foundation
Estate of William J. Glasgow
Estate of Robert E. Gleason
Mr. and Mrs. Robert S. Goldberg
Alfred G. & Hope P. Goldstein Fund
Estate of Helen M. Golen
Mr. & Mrs. Sidney Goodfriend
Mr. and Mrs. Alan L. Greene
Trust of Phyllis A. Greene
Trust of Richard M. Greifer
Estate of Edythe Griffinger
Peter M. Guggenheimer
The Marc Haas Foundation
Mr. and Mrs. William W. Haerther, Jr.
Estate of Ethel V. Haldeman
Evelyn J. A. Hall Charitable Trust
Mr. and Mrs. Stephen L. Hammerman
Estate of Olga V. Hargis
Mr. and Mrs. William B. Harrison, Jr.
Estate of Judith B. Helfant
Trust of Richard V. Henry, Jr.
Estate of Ruth H. Hewlett
Marie B. Hilliard
Trust of Milan M. Holdorf
Trust of Benjamin Holmes
Trust of Karla Homburger
Hope Funds for Cancer Research
Estate of Claire Hughes-Glasgow
The Patricia M. Hynes and Roy L. Reardon Foundation
Hyundai Motor America
Deanne and Arthur Indursky
Invest for Children, a Foundation of Investindustrial
Mrs. H. Anthony Iettleon
Johnson & Johnson
Estate of Horace A. Jones
Fritz and Adelaide Kauffmann Foundation
Mr. and Mrs. Robert B. Kay
Kinetics Foundation
Estate of Joan E. Kinley
Estate of Hazel V. Knapp
Estate of Ruth Koch
The Koodish Family Charitable Trust
The Kronthal Family
The Jacob & Valeria Langeloth Foundation
Trust of Charles T. Larus
Estate of Owen Laster
Lazard Capital Markets
Estate of Anne Leventon
Mr. and Mrs. Allan L. Levey
Dr. Nancy Alpern Levin
Fran and Ralph Levine
Life Raft Group
Estate of Lillian Light
Trust of Catherine M. Lincoln
Estate of Leah W. Linn
Harry J. Lloyd Charitable Trust
Trust of Martin C. and Margaret V. Lohsen
Trust of Louis J. Lombardi
Mr. and Mrs. Edward Lundy
Lung Cancer Research Foundation
Estate of Evelyn P. Lyon
Earle I. Mack Foundation
Estate of Lucille Knowles Freedman Mann
March of Dimes Foundation
Estate of Dana Marin
Estate of Anne Markowitz
Trust of Anthony J. Masard
Max Cure Foundation
Mr. and Mrs. Louis V. Mazzella
Donors to the Campaign for Memorial Sloan Kettering

- Estate of William J. McCann
- Trust of John C. McCormick
- Mr. and Mrs. Thomas R. McCullough
- The James S. McDonnell Foundation
- Estate of Ralph Nelson
- Mesothelioma Applied Research Foundation
- The Merck Company Foundation
- Estate of Ruth Vitow Messias
- Trust of Russell A. Meyer
- Peter Michael Foundation
- The Milbank Foundation for Rehabilitation
- The Norman M. Morris Foundation
- Trust of Paula Moss
- Mr. and Mrs. Charles H. Mott
- Movember
- Muscular Dystrophy Association
- The National Brain Tumor Society
- National Childhood Cancer Foundation
- Carole and Raymond Neag
- News Corporation
- Occidental Petroleum Corporation
- Trust of Melba M. O’Connell
- The Sylvan and Ann Oestreicher Foundation
- Trust of Jo Anne H. Olmsted
- E. Stanley O’Neal
- William C. and Joyce C. O’Neal Charitable Trust
- The Ovarian Cancer Research Fund
- Estate of Beatrice P. K. Palestin
- The Barnaby Foundation
- Estate of Ingeborg K. Watson
- The Wasily Family Foundation
- The Warner Foundation, Inc.
- Walk the Walk America, Inc.
- Vital Projects Fund, Inc.
- Mrs. Jenice Pulver
- Margot Rosenberg Pulitzer Foundation
- Estate of Gerald E. Proctor
- The Perelman Family Foundation
- Party City Corporation
- The Perelman Family Foundation
- The Perkins Fund
- Pershing Square Sohn Cancer Research Alliance
- Estate of Philip W. Pfeifer
- Pfizer Inc.
- Estate of Lucie Picard
- Estate of Marion M. Pincus
- Plastic Surgery Foundation
- Josephine K. Poling
- Ruth Porat and Anthony Paduano
- Polo Ralph Lauren Corporation
- Estate of Gerald E. Proctor
- Margot Rosenberg Pulitzer Foundation
- Mrs. Jenice Pulver
- Project A.L.S.
- PVH Corp.
- The Mitchell P. Rales Family Foundation
- Recanati Foundation
- John Bradbury Reed
- Trust of Irene Dorothy Reel
- Estate of Muriel G. Reich
- Estate of Agnes Rezler
- Trust of Argyll C. Rice
- Estate of Richard A. Riecker
- Louise & Frank Ring
- Mrs. Helena and David Rodbard
- Alexander J. Roepers
- Shafi Roepers
- Trust of William C. Rogers
- Mr. and Mrs. Stephen J. Rosenthal
- The Arthur Ross Foundation, Inc.
- Amanda and David Russekoff
- Trust of Edward G. Ryder
- The Raymond & Beverly Sackler Fund for the Arts and Sciences
- Moise Safra Family
- Dr. Nathan E. Saint-Amand
- Sarcoma Foundation of America
- Estate of George W. Schneider III
- Ira Schneider Memorial Cancer Foundation
- Estate of Alana M. Schuster
- The Seraph Foundation
- Evelyn R. Simmers Charitable Trust
- Suzanne Cohn Simon
- Trust of Barbara K. Snader
- Estate of William E. Snee
- Beatrice Snyder Foundation
- Lavinia Branca Snyder
- The Society of MSK Associates Committee
- Estate of Katherine R. Sonneman
- Spin4Survival
- Trust of Barbara A. Stapleton
- Estate of Helen E. Steadman
- Bonnie and Steven E. Stern
- Trust of Charles M. Stevenson
- The Mel Stottlemeyer Myeloma Foundation
- Trust of James Strobridge
- Mrs. Laure Sudreau-Rippe
- The Michael Sweig Foundation
- J. T. Tai & Co. Foundation
- Ping Y. Tai Foundation
- The Edward N. & Della L. Thome Memorial Foundation, Bank of America, N.A. Trustee
- The Craig D. Tifford Foundation, Inc.
- Trip Advisor
- Barbara Davies Troisi Foundation
- Thomas N. Tryforos
- Estate of Stanley F. Tucker
- Turner Construction Company
- Twenty-First Century Fox, Inc.
- The Tyler Foundation
- United Way of Tri-State
- Trust of Ward M. Vanderpool
- The Vanneck-Bailey Foundation
- Variety – The Children’s Charity
- Richard C. Vergobbi
- Estate of Christine Villano
- Vital Projects Fund, Inc.
- Walk the Walk America, Inc.
- The Warner Foundation, Inc.
- The Walshe Family Foundation
- Estate of Ingeborg K. Watson
- Trust of Thomas J. Watson, Jr.
- Estate of Ruth C. Weismann
- Mr. and Mrs. Harold S. Wertheimer
- WestRock Foundation
- Trust of Reamer W. Wigle
- The David and Ellen Williams Foundation
- Trust of Richard A. Yudkin
- Estate of Anna M. Zavatt
- Ronald Zung

$250,000 — $499,999
- Trust of George Aaron
- Accelerate Brain Cancer Cure (ABC2) Foundation
- Estate of John D. Adams, Jr.
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Adenoid Cystic Carcinoma Research Foundation
- The Louis & Bessie Adler Foundation
- Trust of Sebastian & Helen Albrecht
- The Alliance Against ASPS Foundation
- Trust of Eileen Alpert
- Alzheimer’s Association
- American Asthma Foundation
- American Health Assistance Foundation
- The American Ireland Fund
- The Ametek Foundation, Inc.
- Dorothy A. Anderson
- Anonymous
- Estate of Mark J. Anton
- Estate of Anita S. Appel
- Mr. and Mrs. Frank W. Appleton, Jr.
- Estate of Bente Arquin
- Joyce Ashley
- Estate of Rose Ashton-Irving
- Avon Foundation
- B*Cured
- Estate of William C. Bahn, Jr.
- Gail L. Baird Family Foundation
- The Banbury Fund
- Estate of Iris Baranof
- Trust of Margaret D. Barber
- Estate of Florence Barrack
- Estate of Marcia Batten
- Betsy L. Battle
- Trust of Gertrude E. Beck
- Estate of Grace Becker
- Cheryl K. Beebe and James A. Grimm
- Estate of Ethel A. Bell
- Trust of Virginia Poole Benjamin
- Corinne Berezuk and Michael Stieber
- Bergstein Family Foundation
- Estate of Gertrude G. Bernstein
- The Lisa E. Bilotti Foundation
- The Blackstone Charitable Foundation
- James Blake Foundation
- The Nancy and Robert S. Blank Foundation
- Trust of Ronald M. Blau
- Estate of Ida Bloom
- Albert and Betty Bodian
<table>
<thead>
<tr>
<th>Donors to the Campaign for Memorial Sloan Kettering</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antoinette E. &amp; Herman Boehm Foundation</td>
</tr>
<tr>
<td>Estate of Marthe Bonneau</td>
</tr>
<tr>
<td>Trust of Lillian Borchard</td>
</tr>
<tr>
<td>The Louis L. Borick Foundation</td>
</tr>
<tr>
<td>The Albert C. Bostwick Foundation</td>
</tr>
<tr>
<td>Mr. and Mrs. Kevin A. Bousquette</td>
</tr>
<tr>
<td>Trust of Alice M. Branch</td>
</tr>
<tr>
<td>The Braver Foundation</td>
</tr>
<tr>
<td>Bridgemill Foundation</td>
</tr>
<tr>
<td>Estate of Paul P. Brieloff</td>
</tr>
<tr>
<td>Bright Focus</td>
</tr>
<tr>
<td>The Brightwater Fund, Gloria Jarecki</td>
</tr>
<tr>
<td>Trust of Constantine Brown</td>
</tr>
<tr>
<td>David A. and Merle L. Brown</td>
</tr>
<tr>
<td>Brownstein Hyatt Farber Schreck</td>
</tr>
<tr>
<td>Mr. and Mrs. Norman Brownstein</td>
</tr>
<tr>
<td>Estate of Madalyn B. Bryant</td>
</tr>
<tr>
<td>The Bugas Fund</td>
</tr>
<tr>
<td>Estate of Lillian Burg</td>
</tr>
<tr>
<td>Estate of Marian Butler</td>
</tr>
<tr>
<td>Mr. and Mrs. Donald G. Calder</td>
</tr>
<tr>
<td>Cancer Support Services, Inc.</td>
</tr>
<tr>
<td>The Paul Robert Carey Foundation</td>
</tr>
<tr>
<td>Mr. and Mrs. Michael Carr</td>
</tr>
<tr>
<td>Mark A. Castellano</td>
</tr>
<tr>
<td>Estate of Georgia M. Catrini</td>
</tr>
<tr>
<td>Trust of Ruth C. Celarek</td>
</tr>
<tr>
<td>Estate of Burdette G. Chamberlin</td>
</tr>
<tr>
<td>Trust of Cicely J. Chandler</td>
</tr>
<tr>
<td>Mr. and Mrs. Bernard T. Chaus</td>
</tr>
<tr>
<td>Joan Chorney</td>
</tr>
<tr>
<td>Chris4Life Colon Cancer Foundation</td>
</tr>
<tr>
<td>Florence Chu, MD</td>
</tr>
<tr>
<td>CIBC World Markets Corporation</td>
</tr>
<tr>
<td>The Clark Foundation</td>
</tr>
<tr>
<td>Estate of Gerald Clements</td>
</tr>
<tr>
<td>Estate of Dorothy L. Cobb</td>
</tr>
<tr>
<td>Trust of Joan F. Cobb</td>
</tr>
<tr>
<td>Estate of Frances B. Cohen</td>
</tr>
<tr>
<td>Mr. and Mrs. John K. Colgate, Jr.</td>
</tr>
<tr>
<td>Terry Collins</td>
</tr>
<tr>
<td>The Community Foundation for Northern Virginia – Hanlon Family Fund</td>
</tr>
<tr>
<td>Estate of Robert I. Conley</td>
</tr>
<tr>
<td>Cooley's Anemia Foundation</td>
</tr>
<tr>
<td>Estate of Lillian Copperman</td>
</tr>
<tr>
<td>Carlos A. Cordeiro Foundation</td>
</tr>
<tr>
<td>Estate of Leonard Cossack</td>
</tr>
<tr>
<td>Frederic R. Coudert Foundation</td>
</tr>
<tr>
<td>The Cowles Charitable Trust</td>
</tr>
<tr>
<td>Estate of Mary O. Craft</td>
</tr>
<tr>
<td>Estate of Edna W. Curl</td>
</tr>
<tr>
<td>Filomen M. D’Agostino Foundation Corp.</td>
</tr>
<tr>
<td>Estate of Thomas R. Daly</td>
</tr>
<tr>
<td>Estate of Rosetta Damilano</td>
</tr>
<tr>
<td>Trust of DeWitt S. Davidson</td>
</tr>
<tr>
<td>Guy and Sally Davidson</td>
</tr>
<tr>
<td>Trust of Richard L. Davies</td>
</tr>
<tr>
<td>The Arthur Vining Davis Foundations</td>
</tr>
<tr>
<td>Estate of Frederick W. Davis</td>
</tr>
<tr>
<td>Estate of Leonard Davis</td>
</tr>
<tr>
<td>Trust of Marion E. Dean</td>
</tr>
<tr>
<td>Deborah A. DeCotis</td>
</tr>
<tr>
<td>Estate of Lorraine J. Dehoog</td>
</tr>
<tr>
<td>Trust of Carolyn B. Denney</td>
</tr>
<tr>
<td>The De Rosa Foundation for Colon Cancer Research and Prevention</td>
</tr>
<tr>
<td>The Desmoid Tumor Research Foundation</td>
</tr>
<tr>
<td>Hester Diamond Foundation</td>
</tr>
<tr>
<td>Mr. and Mrs. Lyman B. Dickerson</td>
</tr>
<tr>
<td>The Dickson Foundation</td>
</tr>
<tr>
<td>Estate of Evelyn Z. Diehl</td>
</tr>
<tr>
<td>The DiMenna Foundation, Inc.</td>
</tr>
<tr>
<td>James and Judith K. Dimon</td>
</tr>
<tr>
<td>Elizabeth R. Miller and James G. Dinan and</td>
</tr>
<tr>
<td>The Dinan Family Foundation</td>
</tr>
<tr>
<td>Elizabeth K. Dollard Charitable Trust</td>
</tr>
<tr>
<td>William C. Dowling, Jr. Foundation</td>
</tr>
<tr>
<td>Estate of Laura D. Eastman</td>
</tr>
<tr>
<td>The Eberstadt-Kuffner Fund Inc.</td>
</tr>
<tr>
<td>ECD Global Alliance</td>
</tr>
<tr>
<td>Mr. and Mrs. Thomas J. Edelman</td>
</tr>
<tr>
<td>Mr. and Mrs. Barclay Ehler</td>
</tr>
<tr>
<td>Eli Lilly &amp; Co.</td>
</tr>
<tr>
<td>Estate of Rita H. Schaefer Elliott</td>
</tr>
<tr>
<td>Empire Blue Cross &amp; Blue Shield</td>
</tr>
<tr>
<td>The Charles Engelhard Foundation</td>
</tr>
<tr>
<td>Esophageal Cancer Education Foundation</td>
</tr>
<tr>
<td>Trust of June K. Evans</td>
</tr>
<tr>
<td>Trust of Lillian Evans</td>
</tr>
<tr>
<td>Lord Evans of Watford</td>
</tr>
<tr>
<td>Trust of Sarah W. Ewing</td>
</tr>
<tr>
<td>Mr. and Mrs. Barton Faber</td>
</tr>
<tr>
<td>Estate of Giuliana Fantini</td>
</tr>
<tr>
<td>Trust of Mary E. Farrell</td>
</tr>
<tr>
<td>Estate of Ralph R. Feigelson</td>
</tr>
<tr>
<td>The Feinstein Family Foundation</td>
</tr>
<tr>
<td>The Isabel, Harold, and Gerry Feld Fund for Bereavement</td>
</tr>
<tr>
<td>Hilary Carla Feshbach</td>
</tr>
<tr>
<td>Mrs. Frederick Fialkow</td>
</tr>
<tr>
<td>Estate of Selma Fine</td>
</tr>
<tr>
<td>First Eagle Investment Management</td>
</tr>
<tr>
<td>First Quality Enterprises, Inc.</td>
</tr>
<tr>
<td>Jeanne Donovan Fisher</td>
</tr>
<tr>
<td>The Jodi Spiegel Fisher Cancer Foundation</td>
</tr>
<tr>
<td>Aaron Fleischman and Lin Lougheed</td>
</tr>
<tr>
<td>Foundation</td>
</tr>
<tr>
<td>The Floren Family Foundation</td>
</tr>
<tr>
<td>Fondazione Italiana</td>
</tr>
<tr>
<td>For the Love of Life</td>
</tr>
<tr>
<td>Steve Forbes</td>
</tr>
<tr>
<td>Trust of William Forbes</td>
</tr>
<tr>
<td>Foundation 14</td>
</tr>
<tr>
<td>Mr. and Mrs. Lewis Frankfort</td>
</tr>
<tr>
<td>Trust of Jill and Jayne Franklin</td>
</tr>
<tr>
<td>Frazier Foundation</td>
</tr>
<tr>
<td>Trust of Frank O. Fredericks</td>
</tr>
<tr>
<td>Free to Breathe</td>
</tr>
<tr>
<td>The Fribourg Foundation</td>
</tr>
<tr>
<td>Estate of Gerard M. Friedman</td>
</tr>
<tr>
<td>The Anna Fuller Fund</td>
</tr>
<tr>
<td>Richard M. Furlaud</td>
</tr>
<tr>
<td>Estate of Leonard Galasso</td>
</tr>
<tr>
<td>Estate of Regina M. Gallichio</td>
</tr>
<tr>
<td>Estate of Norman D. Galloway</td>
</tr>
<tr>
<td>Mr. and Mrs. Robert M. Gardiner</td>
</tr>
<tr>
<td>Trust of Esther B. Garnsey</td>
</tr>
<tr>
<td>Trust of Frances L. Gatterdam</td>
</tr>
<tr>
<td>Estate of Mildred B. Gehrke</td>
</tr>
<tr>
<td>General Atlantic Foundation</td>
</tr>
<tr>
<td>The Patrick A. Gerschel Foundation</td>
</tr>
<tr>
<td>Leonardo Giambrone</td>
</tr>
<tr>
<td>The Albert and Pearl Ginsberg Foundation</td>
</tr>
<tr>
<td>Liane Ginsberg</td>
</tr>
<tr>
<td>The Glades Foundation</td>
</tr>
<tr>
<td>Mr. and Mrs. Eugene J. Glaser</td>
</tr>
<tr>
<td>Trust of Marc S. Goldberg</td>
</tr>
<tr>
<td>Corinne and Daniel Goldman</td>
</tr>
<tr>
<td>Susan Wallack Goldstein</td>
</tr>
<tr>
<td>Arthur A. Gosnell</td>
</tr>
<tr>
<td>Estate of Barbara Grace</td>
</tr>
<tr>
<td>Estate of Felice M. Grad</td>
</tr>
<tr>
<td>Graff Diamonds</td>
</tr>
<tr>
<td>Graham Holdings Company</td>
</tr>
<tr>
<td>Granary Associates</td>
</tr>
<tr>
<td>The Grateful Foundation, Inc.</td>
</tr>
<tr>
<td>Susan Zises Green</td>
</tr>
<tr>
<td>Estate of Eldridge A. Greenlee</td>
</tr>
<tr>
<td>Grinberg Family Foundation</td>
</tr>
<tr>
<td>Virginia and Howard Groombridge</td>
</tr>
<tr>
<td>Mr. and Mrs. Martin D. Gross</td>
</tr>
<tr>
<td>Trust of William Gross</td>
</tr>
<tr>
<td>Shoshanna Gruss</td>
</tr>
<tr>
<td>Gurwitch Products</td>
</tr>
<tr>
<td>Robert C. Halboth</td>
</tr>
<tr>
<td>Mrs. Melville W. Hall</td>
</tr>
<tr>
<td>Charles and Sarah Hallac</td>
</tr>
<tr>
<td>Trust of Florence M. Hammer</td>
</tr>
<tr>
<td>Trust of Robert Hanson</td>
</tr>
<tr>
<td>Mr. and Mrs. Jose Kuri Harfush</td>
</tr>
<tr>
<td>Harrington Discovery Institute</td>
</tr>
<tr>
<td>Susanne and Shelley Harrison</td>
</tr>
<tr>
<td>Mr. and Mrs. Robert L. Harteveld</td>
</tr>
<tr>
<td>Trust of Abraham Hases</td>
</tr>
<tr>
<td>Estate of Katherine Hawrylow</td>
</tr>
<tr>
<td>Estate of Irma Hayes</td>
</tr>
<tr>
<td>Hecht and Company Philanthropic Fund</td>
</tr>
<tr>
<td>Mr. and Mrs. Charles Heimbold, Jr.</td>
</tr>
<tr>
<td>Cherie Henderson and David Poppe</td>
</tr>
<tr>
<td>Heyman-Merrin Family Foundation</td>
</tr>
<tr>
<td>Brian J. Higgins</td>
</tr>
<tr>
<td>The Hillcrest Foundation</td>
</tr>
<tr>
<td>James and Angela Ho</td>
</tr>
</tbody>
</table>
Donors to the Campaign for Memorial Sloan Kettering

The Catie Hoch Foundation  Lead Annuity Trust  Yvonne & Arthur Moretti
Estate of Laverne Hodges  Trust of Joseph Lebednik  Ronald and Brenda Morey
Estate of Martha Holloway  The Richard S. and Karen LeFrak Charitable Foundation  Trust of Edmund L. Murray
Mr. and Mrs. D. Gregory Horrigan  In memory of Stacey Leondis  Mustaches For Kids
Estate of Chester S. Howard  Estate of Donald LeRoy  Trust of Louise F. Neely
Estate of Karen L. Hudson  Leukemia Research Foundation  Craig H. Neilsen Foundation
The Howard Hughes Medical Institute  Trust of Leona Levy  Estate of Ann M. Nelson
Syde Hurdus Foundation, Inc.  Bertha and Isaac Liberman Foundation, Inc.  Muriel Neumann
IBM International Foundation  The Anne Boyd Lichtenstein Foundation  Neuroendocrine Tumor Research Foundation
The Interpublic Group of Companies  Estate of Helen Lieber  The Newport Foundation
Bruce H. Jacobs  Estate of John E. Liebmann  Estate of Jane M. Nicholson
Trust of Clyde H. Jacobs  Mr. and Mrs. Richard Lightburn  Trust of Florence S. Nilsson
Harry A. Jacobs, Jr.  Pauline H. Lin  James G. Niven
Janssen Pharmaceutical Products LP  Live4Life Foundation  Fred and Gilda Nobel
Estate of Mira Jelin  Estate of Marian J. Looser  The Lyla Nsouli Foundation for Children’s
Robert Charles Jenkins  LUNGevity Foundation  Brain Cancer Research
The JMB Hope Foundation  MacDonald-Peterson Foundation  Trust of Robert M. Ochs
The Robert Wood Johnson Foundation  MacMillan Family Foundation  George L. Ohrstrom, Jr. Foundation
Estate of Al Jolson  Estate of Julian Malkiel  The Okonite Company
Estate of Robert L. Jones  Manhasset Women’s Coalition Against Breast
Max Kade Foundation, Inc.  Cancer  Grace Oughton Cancer Foundation
The Kahn Charitable Foundation  Estate of Albert Manning  The William & Jane Overman Foundation
Kaleidoscope of Hope Foundation  Estate of Marvin Margolies  Eileen and James A. Paduano
Estate of William Kanter  Mrs. John L. Marion  Parfums de Cœur Ltd.
Edward M. Kaufmann  Susan and Morris Mark  Rosalind and Kenneth Pearlman
Estate of Helen Keena  Trust of Sarah H. Marks  PepsiCo Foundation, Inc.
Trust of Fenton O. Keister  The Marmot Foundation  Trust of Elizabeth Polotaye
Robert J. Keller  Estate of Edith Lipphardt Martens  Precision Medicine Research Associates
J. C. Kellogg Foundation  Estate of Elizabeth Martin  Trust of Helen M. Price
The John R. Kennedy Foundation  Trust of Richard and Betty Martin  Estate of Seymour Price
Kern Family Fund  Estate of Ann L. Martinez  Prudential Financial, Inc.
Pearl Family Foundation  The Lucille and Paul Maslin Foundation  Robert Pufahl
Estate of Patricia A. Kerrigan  Trust of Cecilia Matarazzo  Purdue Pharma LP
The Kettinger Family Foundation  Estate of Michael Matchen  Patricia A. Quick Charitable Trust
Estate of Ursula A. Kildea  Estate of Harry H. Maus  Trust of Harriet C. Rath
Pamela and Dwaine Kimmet  Paul S. May  James N. Rentas 5K Run/Walk
Trust of Estelle Knapp  The Mayday Fund  Trust of Anne Resnner
Trust of Paul and Fran Knight  The Helen & William Mazer Foundation  Estate of Walter E. Rex III
The Greater New York City Affiliate of Susan  MBNA America Bank  The Rice Family Foundation
G. Komen for the Cure  The MBNA Education Foundation  Anne S. Richardson Fund
The Kors Le Pere Foundation  Mary Jane McCarthy  The Ritter Family Foundation
Joel Koschitzky  The Michael W. McCarthy Foundation  Irene Ritter Foundation
The Gwen L. Kosinski Foundation  Mr. and Mrs. Thomas R. McCullough  The Andréa Rizzo Dance Therapy Fund
Mr. and Mrs. Marvin H. Koslow  Mr. and Mrs. Jay H. McDowell  Rosalind and Kenneth Pearlman
The Fred W. Kramer Charitable Trust  Estate of Charles McGreavy  James N. Rentas 5K Run/Walk
Mr. and Mrs. Robert A. Kramer  Estate of Mary T. McKibbin  Trust of Anne Resnner
Mr. Kenneth Kret  Estate of Alan McMaster  Estate of Lillian Robbins
Cheryl Gordon Krongard  Laura Mercier Ovarian Cancer Fund  Mr. and Mrs. Stephen Robert
Trust of Walter C. Kronke  The Reuven Merker Charitable Foundation, Inc.  Robin Hood Foundation
Estate of Ann Kuhlmann  Estate of Despina Messinesi  Estate of Sandra Sheppard Rodgers
Estate of Harriette H. Kussin  Mr. Robert A. Metzler  Estate of Ellen S. Rogoff
Estate of Sidney Lacher  Mr. and Mrs. Thomas R. McCullough  Kenneth C. Rohan
Lake Road Foundation  Mrs. Minot K. Milliken  Ginni Rometty
The Lakeside Foundation  Estate of Dorothea K. Money  Estate of Nathan Rothstein
Mr. and Mrs. Joseph M. La Motta  Young Ae Lim and Joonsikk Moon  Estate of Wilhelmina T. Rouget
Estate of Harriet L. Lampert  Trust of Anny S. Moore  Trust of Cecile N. Ruben
Vivian F. Laube  Diana M. Moore  Trust of Maurice Ruben
Lavelle Fund for the Blind, Inc.  The Iris and Junming Le Foundation
Betty Reid Lawson  The Leila Black Charitable Trust
The Iris and Junming Le Foundation

Improving Patient Outcomes
Donors to the Campaign for Memorial Sloan Kettering

The Selma and Lawrence Ruben Foundation
Mrs. Orhan I. Sadik-Khan
Mrs. Edmond J. Safra
Mr. and Mrs. Herbert E. Saks
Mara and Ricky Sandler
Trust of Erika Saphier
Trust of Paul C. Sawyer
Trust of Edwin & Grace Sayers
Estate of Christine C. Scanlan
Trusts of Anabel M. Scarborough and Walter L. Scarborough
The Milton Schlamach Foundation, Inc.
Mr. and Mrs. Stephen Scherr
Trust of Edward and Irene Schlosser
Trust of Jennie C. Schneider
Mrs. Silvia A. Schnur
Mr. and Mrs. Paul C. Schorr IV
Estate of Evelyn Schrank
Trust of Crystal Schull
Estate of Bertha Schulman
The Schultz Foundation
Mr. and Mrs. John W. Scully
Searle Scholars Program
The Select Equity Group Foundation
The Nina and Ivan Selin Family Foundation
Estate of Sam Seltzer
Mr. Frank Senior
Seventh District Association, Inc.
Estate of Gladys N. Severud
The Shanken Family Foundation
Estate of Odette Sharow
Trust of Minnie M. Shaw
Hope Sheridan Foundation
Renee and Irwin Shishko
Estate of Lillian M. Siemionko
The Grace, George, and Judith Silverburgh Foundation
Trust of Leonard & Ruth Silverman
Leonard and Donna Simon
SIR Foundation
Trust of Angie S. Skinner
The Alan B. Slika Foundation
The Gordon H. and Norma Smith Family Foundation
Estate of Robert A. Smith
Estate of Roberta A. Smith
Ms. Beryl Snyder
Society of New York Workers’ Compensation Bar Association
Roy M. Speer Foundation
The Seth Sprague Educational and Charitable Foundation
Trust of James L. Stackhouse
The Robert Steel Foundation for Pediatric Cancer Research
Trust of Frederick T. Steinberg
The Jeffrey Steiner Family Foundation
Mr. and Mrs. Howard Stern
The Guy M. Stewart Cancer Fund
Estate of Sonia Stolin-Moresco
Trust of May Strang
The Daniel P. Sullivan Clinical Fellowship Fund
Timothy P. Sullivan Charitable Lead Trust
Susquehanna Foundation
Trust of Hazel L. Sutton
The Paula Takacs Foundation for Sarcoma Research
James R. Tanenbaum and Elizabeth M. Scofield
Frank N. Tedesco
Trust of Annette M. Terdina
Estate of Stella R. Thater
Think Pink Rocks
Thrasher Research Fund
Mr. and Mrs. Carol W. Timpson, Jr.
Estate of Michael Z. Toman
The Robert Mize & Isa White Trimble Family Foundation
Mr. Steven Trost
Trust of Irwin C. Unger
United Hospital Fund of New York
United Leukemia Fund Inc.
United Way of New York City
The Lucy & Eleanor S. Upton Charitable Foundation
The Vasey Foundation
Veejay Foundation
Estate of Eleanor B. Vogel
Voices Against Brain Cancer Foundation
Douglas Walker
Estate of Muriel F. Wall
The Bert & Sandra Wasserman Foundation
Marla J. Wasserman
The Scott Weingard Memorial Fund
Mr. and Mrs. Boaz Weinstein
Estate of Elias Weiss
In memory of Marie T. Weiss
John A. Weissenbach and Ann Southworth
Ellie Wells-Lonneing
Trust of Ida Wharton
Whitehall Foundation
John C. Whitehead
Estate of Ruth Whitley
William F. and Barbara K. Whitman
The Helen Hay Whitney Foundation
Mr. and Mrs. Frank C. Whittelsey III
The Jesse R. Wike Charitable Trust
Jacqueline and Robert Willsen
Kendrick B. Wilson III
Mr. and Mrs. Jon Winkelried
Elizabeth Winterbottom
Wooden Nickel Foundation
Trust of Vincent J. Zappolo
Estate of Robert E. Ziegler
Nicholas B. Zoullas
Mr. and Mrs. Jeffrey A. Zucker

$100,000 — $249,999

4Love Project
A & P Foundation
Abbott Laboratories
Abbvie Foundation
The Louis & AnneAbrons Foundation, Inc.
Jean Ackerman
Acorn Foundation
Mr. and Mrs. Laszlo Adam
The Francis X. Ahearn, Sr. Foundation
Roger and Elizabeth Ailes
Daniel G. Alexander
The Shana Alexander Charitable Foundation
Mr. and Mrs. John P. Allen
Robert and Elaine Allen
Alliance for Life Sciences & Health
Estate of Lori S. Alper
Sheikha Noura Alsheikh
Alzheimer’s Association
The Amaturo Foundation, Inc.
American Federation for Aging Research
American Lung Association
American Urological Association
Amgen, Inc.
Estate of Maurice Amzalak
Mr. and Mrs. Harold F. Anderson
Richard and Peggy Anderson
Warren and Lillian Anderson
Anonymous
Mr. and Mrs. Jerome V. Ansell
Anthony Brands
The Antonacci Family Foundation
Maite Aquino Memorial Fund
Mr. and Mrs. Rand V. Araskog
Trust of Theodocia D. Arkus
Mr. and Mrs. William J. Armfield IV
Paul Armin Family Foundation
Nicole Sinek Arnaboldi and Leo Arnaboldi
Kym S. Arnone
The Aronson Family Foundation
Mary Kay Ash Charitable Foundation
The David R. and Patricia D. Atkinson Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
AVIESAN
The Ayres Baechle Foundation
Mr. and Mrs. Charles Ayres
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
The David R. & Patricia D. Atkinson Foundation
Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
AVIESAN
The Ayres Baechle Foundation
Mr. and Mrs. Charles Ayres
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
The David R. & Patricia D. Atkinson Foundation
Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
AVIESAN
The Ayres Baechle Foundation
Mr. and Mrs. Charles Ayres
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
The David R. & Patricia D. Atkinson Foundation
Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
AVIESAN
The Ayres Baechle Foundation
Mr. and Mrs. Charles Ayres
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
The David R. & Patricia D. Atkinson Foundation
Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
AVIESAN
The Ayres Baechle Foundation
Mr. and Mrs. Charles Ayres
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
The David R. & Patricia D. Atkinson Foundation
Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
AVIESAN
The Ayres Baechle Foundation
Mr. and Mrs. Charles Ayres
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
The David R. & Patricia D. Atkinson Foundation
Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
AVIESAN
The Ayres Baechle Foundation
Mr. and Mrs. Charles Ayres
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
The David R. & Patricia D. Atkinson Foundation
Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
AVIESAN
The Ayres Baechle Foundation
Mr. and Mrs. Charles Ayres
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
The David R. & Patricia D. Atkinson Foundation
Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
AVIESAN
The Ayres Baechle Foundation
Mr. and Mrs. Charles Ayres
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
The David R. & Patricia D. Atkinson Foundation
Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
AVIESAN
The Ayres Baechle Foundation
Mr. and Mrs. Charles Ayres
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
The David R. & Patricia D. Atkinson Foundation
Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
AVIESAN
The Ayres Baechle Foundation
Mr. and Mrs. Charles Ayres
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
The David R. & Patricia D. Atkinson Foundation
Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
AVIESAN
The Ayres Baechle Foundation
Mr. and Mrs. Charles Ayres
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
The David R. & Patricia D. Atkinson Foundation
Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
AVIESAN
The Ayres Baechle Foundation
Mr. and Mrs. Charles Ayres
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
The David R. & Patricia D. Atkinson Foundation

2015 AR
Donors to the Campaign for Memorial Sloan Kettering

Estate of Harold P. Bannister
Mr. and Mrs. Robert L. Barbanell
Trust of James R. Barber
Barish Family Foundation
Trust of Grace M. Barry
Estate of Kaethe F. Barry
Estate of Patricia A. Barry
Mario Batali Foundation
Trust of Eileen L. Batten
Trust of Joyce A. Battle
The Modestus Bauer Foundation
Trust of Ruth M. Baughman
Lynn B. Bayard
Be the Difference Foundation
Estate of Thelma Beatty
Trust of John A. Beatty
Mr. and Mrs. Edmund Becker
Estate of Charles R. Beecher
Trust of Kathe Begeest
The Robert & Renee Belfer Family Foundation
Estate of Robert D. Bennett
Corinne Berezuk and Michael Stieber
Trust of Isidore Bergner
Berkowitz II Foundation
Mr. Bernard S. Berkowitz
Joan and James Berkowitz Fund
The Bill Bernbach Foundation
Steffi and Robert Berne
Mrs. Louis Bernstein
Luciano and Giancarla Berti
Jacqueline Bikoff
Estate of Margaret L. Bingman
Biomet
Trust of C. June Bisplinghoff
BJ’s Charitable Foundation
Bladder Cancer Advocacy Network
Trust of Raymond Blake
Blaker Family Fund
Hector Payares Blanco
Bill Blass Licensing Company, Inc.
Mr. and Mrs. Jeff T. Blau
Madeline and Alan S. Blinder
Ambassador and Mrs. Alan J. Blinken
Mr. and Mrs. James A. Block
Estate of Vivian K. Blonder
Trust of George Bloostein
Edith C. Blum Foundation, Inc.
The Walter & Adi Blum Foundation, Inc.
The Walter & Adi Blum Foundation, Inc.
Harold and Adele Blumenkrantz
Estate of Simon P. Blustone
D. Dixon Boardman
Bruce Bocina
Estate of Marti A. Boden
Peter Bodok
Estate of Alan A. Bohlinger
Estate of Marjorie R. Boselly
The Boston Foundation
Estate of Lydia Botfeld
Alan F. Bovee
Trust of William R. Boyle
Estate of Mary C. Brabson
Estate of Elsie L. Bradford
The Bradshaw Family
Brahman Capital
Brain Tumor Funders’ Collaborative
Anna M. and Mark R. Brann
Mr. and Mrs. Henry R. Breck
Milton Brenner
Mr. and Mrs. Fred J. Brettlander
Estate of Mae Bridewell
Trust of Marie H. Brock
The Broder Family Foundation, Inc.
Estate of Edna Brodie
Tom and Meredith Brokaw
Randall Brooks
Brown Helicopter, Inc.
Ms. Betsy Levine-Brown and Mr. Marc Brown
Carl and Nicky Brown
Trust of Ruth Ann Brown
Estate of William A. Brown, Sr.
The Brownington Foundation
Estate of Vernon Brunelle
Elizabeth Bucher
The Peter & Carmen Lucia Buck Foundation
Estate of Edwin Buckingham
Melva Buckbaugh and the Robert I. Goldman Foundation
Janna Bullock
Mr. and Mrs. Roy R. Burmester III
Trust of Florence Bunn
Mr. and Mrs. Franz H. Burda
Estate of Edith R. Burger
Mrs. Coleman P. Burke
Estate of Louise V. Burnett
Janet Burros Memorial Foundation
Mr. and Mrs. Harold Busch
Estate of John D. Bush
Mr. and Mrs. Jonathan J. Bush
The Paul Nabil Bustany Foundation
Gilbert and Ilidiko Butler Family Foundation, Inc.
Estate of Ruth J. Butterworth
Estate of Lillian A. Byman
Mr. and Mrs. Bruce L. Calhoun
Mr. and Mrs. Jeremiah M. Callaghan
Trust of Marilyn Campbell
Cancer Research & Treatment Fund
Leah Rush Cann
James A. Cannon
Estate of Edward A. Cantor
Trust of Jacqueline Carrick
Mr. and Mrs. Edmund M. Carpenter
Mr. and Mrs. Warren E. Carpenter III
Estate of Eugene Carrara
Estate of William K. Carson
Mr. and Mrs. William M. Carson
Estate of Colon B. Carter
Trust of Winfred T. Carter
Estate of Elsie Cartotto
Joan (Perkowski) Cashin Foundation
Casual Male Corp.
Catch 25 Foundation, Inc.
The Cayuga Foundation
Estate of Charlotte A. Celian
Mr. and Mrs. E. Val Cerutti
Trust of George F. Chagnon
Trust of Henry D. Chaikin
Dr. Kalpana Chakraburty
Chanel, Inc.
Margaret Anne Chappell
Charina Foundation
Tribhuvan N. and Sadhna Chaturvedi
Estate of Camille Chercone
Child Neurology Foundation
Childhood Brain Tumor Foundation
The Children’s Brain Tumor Foundation
Children’s Neuroblastoma Cancer Foundation
The Francis and Miranda Childress Foundation
The Jane Coffin Childs Memorial Fund for Medical Research
Chordoma Foundation
Estate of Selma Chyyat
William Joseph Cilberti
Judith Ann Cion Revocable Trust
Estate of Piera Ciriello
Amada Styles Cirelli Foundation for Pediatric Cancer Research
Mr. and Mrs. Robert Citrone
The Anne L. and George H. Clapp Trust
Estate of Lyman W. Clardy
Estate of Ina Clarke
Estate of Mary M. Cleary
Cleveland Clinic Health System
C.I. Group Research Foundation
Mr. and Mrs. Laurence W. Cohen
Clarence L. Coleman Jr. and Lillian S. Coleman Foundation
James J. Coleman, Jr.
Paul Jackson Coleman
Estate of Gertrude T. Coles
Robert and Maryann Collins
Estate of Arthur R. Collins
Estate of Lila V. Collins
The Colon Cancer Foundation
Comerica Charitable Trust
Mr. and Mrs. Alexius Conroy
Consolidated Edison Company of New York
Dudley P. Cook
Mr. and Mrs. Errol M. Cook
Mrs. William B. Cook
Mr. and Mrs. E. Gerald Cooper
Estate of Morris Coppersmith
Estate of G. R. Couch
Courtesy Associates, Inc.
Donors to the Campaign for Memorial Sloan Kettering

Anne Cox Chambers Foundation
Estate of Edith C. Cox
Trust of Burton L. Craig, Jr.
Trust of Franklin C. Craig
W. Michael and Lois Craig
Credit Suisse Group
Trust of Louise Crites
The Crown Family
Bruce Crystal
Trust of Leroy & Barbara Cubicciotti
Cure Alzheimer’s Fund
Mr. and Mrs. James F. Curtis III
Cusa Realty, LLC
Custom Design Communications, Inc.
William J. Cwenn
Mark and Elizabeth Czarnecki
Mrs. Charles A. Dana, Jr.
Estate of Richard Daniels
The Gloria and Sidney Danziger Foundation, Inc.
Estate of Hannah Danziger
The E. S. P. Das Foundation
The Davee Foundation
Estate of Paul D’Aversa
Estate of Hazel Davidson
Mr. and Mrs. Scott E. Davidson
Trust of Jane Davies
The Ellen and Gary Davis Foundation
Roxana V. Dawson
Estate of Sara De Castro
Estate of Karin D. de Chellis
Estate of Jean Decker
Estate of Libiro DeFilippis
The Lawrence and Florence DeGeorge Charitable Trust
The DeGregorio Family Foundation
Lynn DeGregorio
Mr. and Mrs. Roberto de Guardiola
Estate of Katherine C. DeHaan Goff
Anthony Del Bove
The Delaney Family
Estate of Helen Demetriades
Mr. and Mrs. Steven Denning
The Derfner Foundation
Ernst and Paula Deutsch Foundation
The DeWitt Wallace Fund
Mr. and Mrs. Anthony Diaco
The Miriam & Arthur Diamond Charitable Trust
The Ernest & Jeanette Dicker Foundation
Estate of Margaret DiDonato
Estate of Richard I. Diennor
Trust of Mary L. Dillon
Discavage Family Foundation
Mr. and Mrs. Daniel L. Doctoroff
Oliver S. & Jennie R. Donaldson Charitable Trust
Estate of Maurice A. Donovan
John R. Doss
Percy S. Douglas
Susie M. Downing
Mr. and Mrs. Frank P. Doyle
Trust of Max Drechsler
Dreyer’s Grand Ice Cream, Inc.
Estate of Donald E. Drinkwine
Jane Clausen Drorbaugh
Dr. Scholl Foundation
Dr. Jeffrey Duban
Trust of Anne Duerten
Trust of Patricia P. Duffy
Estate of Doris M. Dunham
Margaret H. Dunwiddie
The Durst Organization, Inc.
Estate of Evelyn J. Dyba
The Edelman Family
Thomas Edelman
Doris M. Edwards
E. E. Cruz Company
Mr. and Mrs. Blair W. Effron
Trust of Bertram Ehrlich
Trust of Raymond Ehrlich
Estate of Elinor Ehrman
Estate of Greta Einhorn
Estate of Estelle Eisenstat
Mr. and Mrs. Frederick Elghanayan
Martin Elk League for Cancer Research
Trust of Arnold B. and Joan S. Elkind
Mr. and Mrs. Richard S. Emmet
Andrew J. Entwistle
EOS Products, LLC
Estate of Lillian Epps
Mr. and Mrs. Christopher Errico
Rafael Etzioni
The Charles Evans Foundation
Estate of Eugene M. Evans, Jr.
The Evslin Family Foundation
Trust of James D. Ezell
Gloria B. Falkson
Family Reach Foundation
Fanconi Anemia Research Fund
Mr. and Mrs. Alfonso Fanjul, Jr.
Mr. and Mrs. James T. Fantaci
Estate of Marion E. Feigenbaum
The Alfred & Harriet Feinman Foundation
Gretchen V. and Samuel M. Feldman
The Corinne Feller Memorial Fund
Trust of Robert I. Fendrich
Roger W. Ferguson, Jr.
Trust of Thelma F. Fernandez
Fetzer Institute
Trust of Lydia K. Fiedler
Gloria S. Fine
Randee and Howard Fischer
Estate of James K. Fisher
Estate of Nellie G. Fishman
Estate of William and Frederica Fissell
Trust of Loretta B. Fitzgerald
Mr. and Mrs. Thomas M. Fitzgerald III
James B. Flaws and Marcia D. Weber
The Francis Florio Fund of the New York Community Trust
The Mary Alice Fortin Foundation
Richard N. Foster
Trust of Aida A. Foti
Foundation for Women’s Cancer
Four Seasons Hotel – New York
The Fan Fox and Leslie R. Samuels Foundation, Inc.
Amy K. Foy and Nicholas J. DeFlora
Estate of Thomas R. Foy
Claire and Meyer W. Frank and Leann Frank Charitable Foundation
Trust of Irene R. Frank
Nicole and Steve Frankel
Helen Frankenthaler Foundation
Maria Frangella Foundation For Colon Cancer Research
Mr. and Mrs. David Lee Frankfurt
Trust of James and Mary Frankhouser
Mr. Edward W. Frantel
The Freed Foundation
Estate of Gloria Freed
Estate of Katherine Freeman
Mr. and Mrs. Sanford Freiman
Frey Family Foundation, Inc.
Zoltan Fried
Susan and Fred Friedman
Estate of Eugenie Froemer
Charles A. Frueauff Foundation
Estate of Roger M. Furiness
Estate of Joseph F. Fursa, Jr.
Mr. and Mrs. Thomas J. Gahan
Trust of Ralph W. Gaines
Estate of Anne Gallagher
Anita C. Garoppolo
Mr. and Mrs. Julius R. Gaudio
GC for a Cure 5K Run/Walk
Bruce G. Geary Foundation
Trust of Louis C. Geiger
Trust of William G. Genner, Sr.
Kara and Peter Georgiopoulos
Estate of Jacques A. Gerard
Robert & Sylvia Gergen
Estate of Charles J. Gerhart
Panayotis Gerolymatos
Trust of Alda Getti
Estate of Theresa A. Ghiringhello
Judith Gibbons and Francesco Scattone
The Ryan Gibson Foundation
Marlene and Alan Gilbert
Estate of Rosemarie M. Gilman
Mrs. Bruce A. Gimbel
Trust of Adele Ginsburg
Mr. and Mrs. William H. Girvan
The Harvey S. Gitlin Family Foundation
Gail C. Gittleson
Estate of Grace E. Glenn
Donors to the Campaign for Memorial Sloan Kettering

Glenwood Management Corporation
Trust of Carmen Gobbi
Trust of Glenn R. Gobble
Christina and Peter Gold
Mr. and Mrs. Bradley Goldberg
Leslie H. Goldberg
The Goldhirsh Foundation
Goldhirsh-Yellin Foundation
Estate of Elizabeth B. Golding
Ms. Miriam Goldman
The Barbara L. Goldsmith Foundation
Shelley and Graham Goldsmith
Lawrence Goldstone, MD
Trust of Manuel and Anne Goodman
Trust of Steve Gorczyca
The Gordon Family Foundation, Inc.
Christy and Sheldon Gordon
Trust of Louise S. Gosse
Marietta A. Goulardris
Julie Gould Fund for Medical Research
Estate of Richard P. Gould
Grantham Mayo Van Otterloo & Co.
Estate of Harvey R. Graveline
The Greenberg Breast Cancer Research Foundation
Stephen and Myrna Greenberg
Brigadier General and
Mrs. William S. Greenberg
Mr. and Mrs. Peter S. Gregory
Trust of Dorothy G. Griffin
John and Amy Griffin Foundation
Mr. and Mrs. Melvin W. Griffin
Trust of William C. Griffith, Jr.
Trust of Vernon H. Grigg
Grodetsky Family Foundation
Estate of Evelyn Gross
Estate of J. Stanley Gross
Trust of Lambert J. Gross
Trust of Anthony Grosso
Allen J. Grubman
Audrey and Martin Gruss Foundation
Estate of Wanda Grzymala
Guardsmark, LLC
Marilynn B. Gula Mountains of Hope Foundation
Estate of Pauline R. Gulau
Trust of Elizabeth Guon
Drs. Satyendra and Manjula Gupta
Gurney Foundation
Estate of Gloria E. Gurney
Mimi and Peter Haas Fund
Hachette Filipacchi Media U.S.
Jayma Meyer Hack and Bruce L. Hack
The Hagedorn Fund
The Laverna Hahn Trust
Estate of Margaret S. Hahn
Hairy Cell Leukemia Foundation
Martin and Deborah Hale
Estate of Elizabeth W. Hall
Estate of Mazie J. Hall
Estate of Helen Sue Hameetman
Jeanne G. Hamilton and Lawson W. Hamilton, Jr.
Family Foundation, Inc.
Milton and Miriam Handler Foundation
Estate of Stanley E. Handman
Trust of Elaine A. Hansen
Estate of Marion K. Hardwicke
The Mary Jane Harrington Foundation
Leonard B. Hart
Laura Hartenbaum Breast Cancer Foundation
Mr. and Mrs. William R. Hartong
The Abbe & Lloyd Hascoe Foundation
Have A Chance, Inc.
Trust of Peter J. Hayes
Haymakers for Hope
Morris A. Hazan Family Foundation
HCCF Foundation
Mr. and Mrs. Andrew P. Heaney
Trust of Lonie G. Hearns
The Per and Astrid Heidenreich Family Foundation
Trust of Shirley S. Heiligenman
Mr. and Mrs. Robert M. Hendrickson
Mr. and Mrs. John Hennessy
The Maxine R. and Richard L. Henry Trust
Estate of Robert Hensel, Jr.
The John & Rose Herman Foundation
Carolina Herrera, Ltd.
Trust of Leon Hershaft
Ms. Marlene Hess and Mr. Jim Zirin
Trust of Marie Hesselbach
Heymann-Wolf Foundation
Estate of Manny Hilman
Hillenbrand Family Foundation
Mrs. John S. Hilson
The Mark Hindy Charitable Foundation
Trust of Myfanwy Hinkle
Estate of Vladimir Hladik
Estate of Edward B. Hodge
Estate of Agnes S. V. Hoffman
Estate of Marion Hoffman
Estate of Ruth M. Hoffman
Trust of Steward B. Hoffman, Sr.
Hoffman-La Roche Inc.
Deborah H. and Sigmar K. Hofmann
Hope V. Hofmann
Richard Hogan and Carron Sherry
Mrs. Carolyn T. Holden
Trust of Burt Holtzman
Howard and Carol Holtzmann
Estate of Margaret Hooghius
Estate of Herman L. Hoops
Trust of Anita S. Horbacz
Alfred Samson Hou
Robert Howard Family Foundation
Estate of Frank Huber
Nancy Hughes
Hummanscale Corporation
Estate of Edna Hunt
Carol Hunter
Constance D. Hunter
Estate of Edith M. Hunter
James B. Hunter
I Back Jack Foundation, Inc.
Mr. and Mrs. David W. Ichel
Estate of Priscilla T. Iden
Inamed Corporation
Incyte Corporation
Ingersoll Rand Company
Mr. and Mrs. William H. Ingram
International Myeloma Foundation
Irish Society of Medical Oncology
It Figures LLC
Jacobus-Iacobucci Foundation
Estate of Harold F. Jaeger
Mr. and Mrs. Stanley R. Jaffe
Thomas Jaffe
Family Foundation
JDRF
Trust of Ann E. Jennings
Richard H. Jenrette
The Jewish Communal Fund
Mr. and Mrs. Peter James Johnson, Jr.
The Samuel C. Johnson Trust
J.P. Wish Fund
Trust of Frank J. Kahn
Trust of Nina M. Kaiser
Jane Kalmus
Harry P. Kamen Family Foundation
Mr. and Mrs. Daniel B. Kamensky
Trust of Mildred Kaminsky
Kanarek Family Foundation
Estate of Lee L. Kanarian
Estate of Eleanor Kane
Mr. and Mrs. William Kane
Estate of Bernard Kantor
Steve and Meghan Kanzer
Estate of Irvin L. Kaplan
Marie H. Karger
The Karma Foundation
George Karnoutsos
Trust of Jerry Katz
Trust of Toby Katz
Trust of John Kaufmann, Jr.
Trust of Ralph W. Kaufmann
Mr. and Mrs. Robert M. Kavner
Carl Michael Kawaja and
Gwendolyn N. Holcombe
Thomas F. Kearns
Charles L. Keith & Clara Miller Foundation
Trust of Jacqueline J. Kelly
Estate of Ruth C. Kelly
Mrs. Ann Kelman and the late
Dr. Charles D. Kelman
Kemmerer Family Foundation
Eleanor and Michael Kennedy
Donors to the Campaign for Memorial Sloan Kettering

Peter Kenner Family Fund
J. Kevin Kenny
Kensico Capital Management
John A. Kent
Estate of Herman Kerner
Estate of Charles L. Kerstein
The Glenn D. Kesselhaut Children’s Joy Fund
Estate of Mary F. Kessler
Mr. and Mrs. Peter A. Kessler
Coyla E. Ketchy
Estate of Henri Khouri
Doris and Floyd Kimble Foundation
The King Family Charitable Lead Trust
Mr. James W. Kinnear II
Patricia A. Kirby
Mr. and Mrs. James M. Klausmann
David L. Klein, Jr. Foundation
Robert D. Klemme
The Esther and Joseph Klingenstein Fund
Mr. and Mrs. Steven B. Klinsky
Fernand Koch
Estate of Gale K. Kokubu
Estate of Elizabeth Koller
Mrs. Mitzi Koo
The Koppelman Family Foundation
Robert A. Kotick
Mr. and Mrs. Bruce S. Kovner
Oliver Kramer
Trust of Clara R. Kraut
Mr. and Mrs. Jerome I. Kroll
Trust of Grace E. Kruse
Lee and Murray Kushner
KVFF Fund
Dina Hubell and the Labkon Family
Mrs. Thomas G. Labrecque
Estate of Sidney J. Lacher
Estate of Schubert L. Lamb
Deborah & Peter Lamm
Estate of Marvdene B. LaMonica
The Edward & Kinga Lampert Foundation
Mr. and Mrs. Barry Lang
Estate of Annie Langen
Estate of Anne Lanigen
J. Clair and Pamela Lanning
The Matthew Larson Foundation for Pediatric Brain Tumors
Dr. Gerald D. Laubach
Mrs. Lois H. Lazaro
The M.J. & Carol G. Lebeworth Foundation
Trust of Edwin S. Lee, Jr.
Mr. and Mrs. Thomas V. Leeds
Gary Leet
The Lefkofsky Family Foundation
Lehman Brothers Inc.
Karen and James Lehrburger
Mr. and Mrs. Lewis E. Lehrman
Trust of Martha B. Leigh
Estate of Helen Lesniowski
The Leukemia & Lymphoma Society

Estate of Barbara Grande LeVine
Laurence W. Levine Foundation
Estate of Dina Levinsky
Elvire Levy
Estate of Erna T. Lewine
Mr. and Mrs. Robert Liberman
The Marvin and Kay Lichtman Foundation
Light of Life Foundation
Linda Lipay
Trust of Wilhelmina I. Lipfert
Mr. and Mrs. Ira A. Lipman
Lisa’s Heart Kids’ Cancer Research Fund
The Harold I. & Faye B. Liss Foundation
Mr. and Mrs. Martin Liss
The Litterman Family Foundation
Estate of Seymour Litwack
The Lucius N. Littauer Foundation
Live, Love, Laugh Foundation
Estate of Santina Livolsi
Demarest Lloyd, Jr. Foundation
Jeanette and Peter Loeb
Stephanie and James Loeffler
Long Island League to Abolish Cancer
Estate of Margaret S. Longwell
Estate of Anthony Lopez
Mr. and Mrs. Martin Liss
Losritto Family
Dr. Christine B. Loveland
Milton Lowenstein
James J. and Marianne B. Lowrey
The Lucerne Foundation
Cynthia and Dan Lufkin
Eric and Susan Luse
Ronald S. Lux
Mr. and Mrs. Alexander P. Lynch
Trust of John F. Lynch
Estate of Kathleen E. Lynch
Estate of Charles S. Lyons
Estate of Melvin E. Lyons
Josiah Macy, Jr. Foundation
Arthur & Holly Magill Foundation
John Magnier
The Maguy Foundation
The Arthur I. and Susan Maier Foundation
Estate of Margaret E. Maibl
Estate of Margaret H. Mairs
Trust of Helen E. Major
Estate of Mariette P. C. Major
Estate of Morris Major
Estate of Walter Malen
Herbert J. Maletz
Estate of Irving and Harriet Malitzon
Peter J. Malkin
Elissa Caterfino Mandel
Karen G. Mandelbaum
Estate of Harry Marder
Estate of Ida Mae Margolis
Trust of Carlton G. Marie
Edward J. Marino

Jerome S. and Maria Markowitz
Zvi and Linda Markowitz
Estate of Benjamin Marmer
Karen Marshon
The Christina & Paul Martin Foundation
Mr. and Mrs. Roman Martinez IV
Dorothy Marx
Jo-Ann Marx, MD
Estate of Johanna Marx
Estate of Rita B. Masse
Mary Jane Massie, MD and
Mr. William E. Pelton
James Mathos
Mr. and Mrs. Howard A. Matlin
The Hale Matthews Foundation
Trust of Walter J. Matthews
The Matt’s Promise Foundation
Reuben and Rose Mattus and Doris and
Kevin Hurley Foundation
Maverick Capital Charities
Max Mara USA, Inc.
Mr. and Mrs. Hamish Maxwell
Maynard Childhood Cancer Foundation
Mr. Michael Mazzucca
Estate of Ralph L. McBean
Estate of Ann C. McBride
Estate of Donald J. McCarraher
Estate of John C. McDansels
Mr. and Mrs. Jeffrey A. McDermott
McDonald Financial Group
Lee McDonald
Ralph McDonough
The Dextra Baldwin McGonagle Foundation
McGraw-Hill Companies
McKeen Fund
Mr. and Mrs. Edward B. McKeough
The McKnight Endowment Fund for Neuroscience
Estate of Geoffrey McLoughlin
Estate of Mary E. McMaster
Mr. and Mrs. David B. McQueary
The Melville Foundation
Mr. and Mrs. Keith A. Meister
Melanoma Research Foundation
The Melville Foundation
Mr. and Mrs. Prakash Melwani
Estate of Dorris M. Mendelsohn
Estate of Irving M. Mendelson
Richard and Ronay Menschel
Estate of Lorraine Mensing
Julia and Gilbert Merrill Foundation
Estate of Amy Joan Meskin
Trust of Ruth W. Metcalfe
Mr. and Mrs. Frank A. Metz, Jr.
Estate of Abby E. Meyer
Estate of Ursula Meyer
The Emanuel N. Micaleff Foundation
Mrs. Sidney Michael
Trust of William M. Michaelson
Donors to the Campaign for Memorial Sloan Kettering

Trust of Florence B. Mickels
Cristine Meredith Miele Foundation
The Mike and Steve Foundation
Elaine P. Miles
Eleanor F. Miley
Romeo Milio Lynch Syndrome Foundation
Carolyn Rosen Miller Family Foundation
Mr. and Mrs. Donald K. Miller
Mr. and Mrs. Larry J. Miller
Mr. and Mrs. Matthew Miller
Mr. and Mrs. Richard A. Miller
Mrs. Mary E. S. Milligan
Monroe & Judith Milstein
Philanthropic Fund
Estate of Dorothy B. Minard
Allen Minsky
Melissa and Robert Mittman
Leslie M. Modell
Trust of Nettie Moffenson
Estate of Catherine Mohan
Estate of Irene Mokrzycki
Trust of Celestine Elizabeth Moloney
Estate of William Monaghan
Pauline M. Monteleone
Arthur R. Montgomery
John and Hee-Jung Moon
Estate of Pauline Moor
Mr. and Mrs. Charles V. Moore
The Gordon and Betty Moore Foundation
Estate of Percy W. Moore
Tom & Judy Moore Foundation
The Garrett and Mary Moran Trust
Estate of Barbara B. Morgan
Melissa and Chappy Morris
Alfred L. and Annette S. Morse Foundation
Ken and Linda Mortenson
The Owen Moscone Foundation
Mr. and Mrs. George K. Moss
Manuel and Mercedes Mosteiro
Lisa and Marcelo Mottesi
Virginia M. Mueller
Estate of Irving Mule
Mrs. Sandy Mulligan
Estate of Earl Muroff
Mr. and Mrs. Thomas W. Murphy II
Ernest Muth
Edith L. Nathanson
The National Genetics Foundation, Inc.
NBC Universal
Estate of Gwendolyn L. Nekrewich
Estate of Leslie A. Nelkin
Trust of Jerome Nerenberg
Jane R. Nessen
New York City District Council of Carpenters
Relief and Charity Fund
New York State Health Foundation
The New York Stem Cell Foundation
Gerald L. Nichols and Jacqueline W. Nichols Foundation
Joseph P. Noonan
Trust of Robert F. Novak
The Nussbaum/Kuhn Foundation
NYS Fraternal Order of Police Foundation
The Michael A. O’Bannon Foundation
Estate of James O’Brien
Estate of Ernestine A. O’Connell
Mr. and Mrs. Jeremiah O’Connor
Trust of Emily C. O’Grady
Dara and Tim O’Harra
Estate of Grace O’Hare
Wendy O’Neill
The Oceanic Heritage Foundation
Mr. and Mrs. Wm. Montague Oeste, Jr.
Oki Data Americas, Inc.
Harold N.Openshaw, Jr.
Mr. and Mrs. John D. Opie
The Katie Oppo Research Foundation
Optiscan
Estate of Elaine Orbach
The Orchard Farm Foundation
Otis Elevator Company
Mr. and Mrs. Gunnar S. Overstrom III
William and Ella Owens
Medical Research Foundation
Mr. and Mrs. Neil Padron
Mr. and Mrs. Gregory K. Palm
Pam’s Pals Inc.
Daniel P. and Nancy C. Paduano
Family Foundation
Mr. and Mrs. Jordan M. Pantzer
The Parnassus Foundation
Rosalie Pataro
Trust of Edith Pattison
Estate of Herman L. Paul, Jr.
Richard S. Pechter
Pediatric Brain Tumor Foundation
Pelvis-Mayton Foundation
Trust of James A. Pemberton
Mrs. Richard T. Perkin
Mort Perlooth
Lisa and Richard Perry
The Pershing Square Foundation
Estate of Ruth Peterson
Estate of Frederick D. Petrie
The Pew Charitable Trusts
Mr. Donald Pfanz
Samantha and Ernst Pfenninger
Trust of Peter H. Pfluug
Mr. and Mrs. Francois de Saint Phalle
Phelps Family Foundation
Phoebe’s Phiinds, Inc.
Estate of Edmund Piascecki
Trust of Charles V. Pickup
Estate of Irene Pickup
Alicia and Corey Pinkston
Mr. Alessandro Pinto
Mr. and Mrs. Roy R. Plum
Estate of Beatrice Pockrass
Estate of John E. Polek
Mr. and Mrs. Gerard Pompilio
The Ponagansett Foundation, Inc.
Janis Z. Porch
Trust of Ann C. Porterfield
Dennis B. Poster
Estate of Edna G. Potter
Estate of John A. Powers
John and Jane Powers Foundation
Trust of Ruth S. Prall
Prevent Cancer Foundation
Rita Price
The Procter & Gamble Company
Estate of Ardyss M. and Harold I. Proctor
Project Ladybug, Inc.
The William H. Proscov Foundation
Trust of Raymond F. Prussing
Dr. and Mrs. Mark Ptashine
Richard I. Purnell Fund
Estate of Richard I. Purnell
Bambi Lyman Putnam
Trust of Anna Marie Putti
Roselyn Flaum Radcliffe
Trust of Samuel J. Radcliffe, Jr.
Stewart Rahr
Trust of Betty Raiff
Richard E. Rainwater
Norman R. and Ruth Rales Foundation
Rally Foundation
Mary L. Ralph Philanthropic Fund
Mr. and Mrs. Edward A. Rankin
Theodore A. Rapp Foundation
John H. Rassweller
Abigail T. Reardon
Estate of Phyllis E. Redmerski
Elenore Reed
Estate of Martha Cuneo Reed
Estate of Samuel P. Reed
Compton Rees, Jr.
Odette Regine Foundation
The Beatrice Renfield Foundation
Mr. and Mrs. Ira L. Rennert
Trust of Ruben & Helga Resnik
Olivier and Yosun Reza
The Audrey Rheinstrom and
Anne Blevins Fund
Estate of Roland S. Rhode
Judy Rhulen and Family
Martin Rich
Trust of A. Leslie Richardson
Dr. and Mrs. Peter C. Richardson
Dee Dee Ricks
Trust of Margaret L. Rigby
Estate of Harry Rinehimer
Estate of Elizabeth M. Ringo
Trust of Victoria Rinius
The Fannie E. Rippel Foundation
Estate of Norma Risman
Abigail Rittmeyer
Donors to the Campaign for Memorial Sloan Kettering

The RMF Family Fund, Inc.
Bernard and Elaine Roberts
Estate of Floyd B. Roberts
Trust of Irene M. Roberts
Vivien Rock
Rodale, Inc.
Robert and Aradh Rodale Family Foundation
Estate of Maria Rolfe
Sheldon Rose
Taryn Rose International
Estate of Sylvia Rosenberg
Trust of Ilsa Rosenblum
Trust of Evelyn Rosenstein
Jeffrey Rosenzweig Foundation for Pancreatic Cancer Research
Leo Rosner Foundation
Estate of Barbara Ross
Mrs. Howard L. Ross
Estate of Sylvia Ross
Estate of Eva L. Rothberg
Philip and Marcia Rothblum Foundation
Mr. and Mrs. Eric A. Rothfeld
Estate of Eleanor S. Rothstein
Estate of Geraldine E. Rove
Denise Rover
Fran and Jeff Rowbottom
Mr. and Mrs. Charles Royce
Estate of Pearl Rubin
Rose G. Rubenstein
Mr. and Mrs. Mitchell E. Rudin
Estate of Maria Stella Ruggirello
Estate of Katherine L. Rummel
The Russell Family
Estate of Roberta Russo
Estate of Eileen B. Ruthrauff
The Derald H. Ruttenberg Foundation
Trust of Anne I. Ryan
Andrew Sabin Family Foundation
Martin Sabowitz and Muriel Goldrich
The Saibel Foundation
Estate of V. Edward Salamon
Mr. and Mrs. Eugene L. Salem
Mr. and Mrs. William B. Salomon
Trust of Rose K. Salzwas
Trust of Sidney Samuels
Henry Sanborn
Estate of Andrew D. Sanders
The Sandler Family
Nina and Julian Sandler Charitable Fund
Lt. Colonel (Ret.) Joseph Santa Barbara
Mrs. Barbara Santangelo
The Isabella Santos Foundation
The Sass Foundation for Medical Research
The Saw Island Foundation
Estate of Ida M. Scagliairini
Scalamandre Silks
Didi and Oscar S. Schafer
Peter L. Schaffer
Estate of Richard Scharff
Estate of Sylvia Schatzman
The LeRoy Schecter Foundation
Bill Scherman and Holly Joyner
Pasco L. Schiavo
The Sarah I. Schieffelin Residuary Trust
Estate of Josephine L. Schiff
Estate of Billie Schneider
Mr. and Mrs. Robert Schneider
The Schneider-Kaufmann Foundation, Inc.
Trust of Edward K. Schnepf
Adolph & Ruth Schnurmacher Foundation
Trust of Lola Schug
Estate of Harold B. Schwartz
Theodore G. Schwartz Family Foundation
Estate of Rosalind Schwartzbach
Trust of Paul J. Schwarz
Mr. and Mrs. Michael S. Smith
Mrs. Arline Schwarzman
Mr. and Mrs. Stephen A. Schwarzman
Trust of Robert E. Schwendeman
Mr. and Mrs. Jeffrey E. Schwartz
Trust of Robert E. Schweng
Estate of Jewel C. Seab
Secunda Family Foundation
The Jean & Charles Segal Foundation
Janet Prindle Seidler Foundation
Mr. David Sekiguchi
Rena Selden
The Maryam and Hervey Seley Foundation
Rosemary Selky
R. B. Sellers Foundation
Dominique Senequier
Sephardic Hospital Fund – Medstar
The Jacqueline Seroussi Memorial Foundation
L. J. Sevin
Harold Shames
Estate of Reuben Shane
Trust of Robert A. Shanley
Estate of Saul Shapiro
The Sharma Foundation
Trust of Margaret S. Sharp
Mrs. Patricia C. Shaw
Estate of Bernice Baruch Shawl
Estate of Alice Sherwin
The Shevell Family
Estate of Leo A. Shifrin, MD
Mr. and Mrs. Stanley B. Shokhorn
Mr. and Mrs. William Shulevitz
Mr. and Mrs. Steven J. Sidewater
Muriel F. Siebert Foundation
Estate of Ruth Siegmann
Estate of Mary Siekert
Trust of Walter Silberfarb
Mr. and Mrs. Robert H. Silver
The Slomo & Cindy Silvian Foundation
The Seymour Simon Charitable Trust
Marilyn M. Simpson Charitable Trust
Simpson Thacher & Bartlett Trust
Trust of Marie A. Sinclair
Trust of Otto K. & Harriet J. Singer
Estate of Shirley Singer
Estate of Madeline Sisak
Estate of Evelyn M. Skolnic
SL 2005 Family Trust
Estate of Alvin F. Sloan
Dr. and Mrs. Bernard E. Small
Suse Smetana
Louis and Dora Smith Foundation, Inc.
The Randall and Kathryn Smith Foundation
Mr. Robert J. Smith
Estate of Woodrow Q. Smith
Estate of Dorothy Smolen
Catherine M. Smolich
Trust of Robert J. Smutny
Mr. and Mrs. Jay T. Snyder
Valerie L. Sodano
The Harry & Estelle Soicher Foundation
Trust of Robert Solnick
Solving Kids' Cancer
Therese and Marshall Sonenshine
Professor and Mrs. C. Alan Soons
Estate of Sharon Sorok
Soros Fund Charitable Foundation
JMCRIJ Sorrell Foundation
Sotheby's
The Honorable Joyce L. Sparrow
Estate of Manette H. Speas
Adam R. Spector Foundation
Mr. and Mrs. Richard A. Speike
Trust of Henry Spendel
Estate of Regina W. Spence
Alvira R. Spencer
Estate of DeAnne Spencer
Estate of Agnes Spillmer
The St. Giles Foundation
Ronald Stafford Cancer Support Foundation, Inc.
Trust of Ruth M. Stafford
Walter Stamm
Staten Island Yacht Sales, Inc.
Mr. and Mrs. Robert A. Staub
Esta Eiger Stecher
Mr. and Mrs. Edward C. Steele
Estate of Sanford L. Steelman
Estate of Dennis Stein
The Fred & Sharon Stein Foundation
Mrs. Nancy Steinfield
The Ernest E. Stempel Foundation
The Aaron and Betty Lee Stern Foundation
Estate of Irene Stern
Estate of Winona H. Stevens
J. McLain Stewart
Estate of Rebecca Stohl
Mr. and Mrs. Stuart P. Stoller
Mr. and Mrs. Norman L. Stone
Stony Wold-Herbert Foundation
Estate of Martha W. Stouffer
Estate of Clair B. Stough
Donors to the Campaign for Memorial Sloan Kettering

Estate of Gene K. Strange
Estate of Alice K. Straschil
Estate of Herta Strauss
Lauri Strauss Leukemia Foundation
Geraldine Stutz Trust Inc.
Trust of Mary R. Suchanski
Mr. and Mrs. Robert J. Sullivan
Trust of George O. Summers
Susquehanna Foundation
David W. Sussman
Phyllis and Bernard Sussman
Estate of Sandra Syms
The Taft Foundation
Dorothy D. Taggart Trust
Trust of Andrew Taras
Trust of Joyce A. Taras
Edward Tarby
Target MarkeTeam, Inc.
Estate of Ruth N. Taub
Tay-bandz, Inc.
Estate of Florence G. Taylor
Estate of Gertrude S. Taylor
Trust of James M. Taylor
Team Connor Cancer Foundation
Team Luke vs. Neuroblastoma
The Sidney and Loretta Teich Foundation
Telethon Italy – US Foundation
Estate of Walter G. Terwedow
The T. F. Trust
Thank Heaven Foundation
Estate of Theresa M. Thingelstad
Mr. and Mrs. Andrew S. Thomas
Estate of Robert P. Thome
Trust of Robert W. and Pauline Z. Thompson
Trust of Vernon Thompson
The Vernon F. & Mae E. Thompson Charitable Foundation
Thrill Hill Productions
Tiffany & Co.
Mr. and Mrs. Alexander Tisch
The Laurie M. Tisch Illumination Fund
Estate of Margaret R. Tomas
Trust of Bertha Tomaska
Estate of Milton Topolsky
Estate of John J. Tormey
The Tortuga Foundation
Estate of Virginia M. Toth
Trust of Angelina Ann Tovar
Mr. and Mrs. David C. Tracey
Jill Tracey
Estate of Rita L. Tracey
Trust of Helen A. Trahin
Trust of Dorothy B. Traufield
Beatrice Travis-Cole
The Bud Traynor Memorial Fund, Inc.
The W. James & Jane K. Truettner Foundation
Estate of Ina Tuckman
Estate of R. Read Tull
Lucien L. and Shirley Turk
John J. Twomey
Ahavas Tzdeek Foundation
David V. Uihlein, Sr.
Elaine L. Ullrich
The Unger Family Foundation, Inc.
Mr. and Mrs. Mark D. Unger
The Valley Foundation
Valley of the Sun United Way
The van Ameringen Foundation
Estate of June A. Vanderpool
Jonathan and Sarah Vanica (GSGives)
Varhegyn Foundation
The Varnum DeRose Trust
Dr. Terry G. Vavra and Linda F. Vavra
In memory of Madeline C. Verducci
Estate of Andrea M. Vernick
The Victoria's Smile Foundation
Trust of Eva Vida
The Family of Maria Elena Villanueva
Estate of Dorothy Voelker
Trust of Anna L. Vogel
Estate of Gertrude Vogel
Ralph W. Voit
Trust of Beverly Wachtel
Wachtell, Lipton, Rosen & Katz
The Paul E. and Mary Wagner Trust
Estate of Lillie M. Waldon
Wallace Special Projects Fund
Mr. and Mrs. Paul D. Walsh
Estate of Frances M. Wanek
Estate of Shirley I. Warner
Warren/Soden/Hopkins Family Foundation
Mr. and Mrs. Bruce Wasserstein
Elizabeth T. Wassmundt
Estate of Shirley F. Watkins
Samuel Waxman Cancer Research Foundation
Mr. and Mrs. Peter Webster
Mr. and Mrs. Bradford G. Weekes III
Mr. and Mrs. John G. Weiger
Trust of Gertrude H. Weiler
Mrs. John L. Weinberg
Marc S. Weinberger
Stephen L. Weiner
Danny M. Weinheim
The Isak & Rose Weinman Foundation, Inc.
Estate of Louis Weinstock
Mr. and Mrs. Michael Weisberg
Andrew and Ronnie Weiss
Estate of Gertrude Weiss
Jill and Jeffrey Weiss
Trust of Gertrude Welleich
The Nina W. Werblow Charitable Trust
Estate of Robert L. Werner
Virginia A. Werner
Estate of E. Olga Wesner
Mrs. Elizabeth G. Weymouth
When Everyone Survives
Estate of Frank A. Widenski
Nancy P. Widmer
Mr. and Mrs. Gene Wilder
Mr. Daniel Wilderman and Ms. Barbara Rockenbach
Wilderness Point Foundation
The Wilf Family Foundation
Andrea J. Will Memorial Foundation
Barbara F. Williams
Mr. and Mrs. Eugene F. Williams III
Estate of Phyllis E. Williams
Williams Trading LLC
Trust of Helen A. Wilson
The Winters Family Fund
Helen & Stanley Wissak
Michel C. Witmer
Estate of James B. Wittrock
The Henry Wolf Foundation
Trust of Toby Wolfberg
Alice Aeschliman Wolfe
Mrs. Barbara Wolfson
Trust of Maria Wolter
Estate of Gordon Wootton
Deborah C. Wright
Trust of Twylia H. Wright
Estate of Bernadette Wyrough
Ofer J. Yardeni
Mary and Bob Yellowlees
Estate of Arthur P. Young
Estate of Ellen Youngelson
Alfred D. Youngwood
Zegar Family Foundation
The Patricia J. and Edward W. Zeh Charitable Foundation
The Zickler Family Foundation
The Isaac Ziegler Charitable Trust
Stanley Shalom Zielony Foundation
Martha E. Zimmer
Larry and Anne Zimmerman

When Everyone Survives
The Society of Memorial Sloan Kettering Cancer Center Administrative Board

EXECUTIVE COMMITTEE

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAVINIA BRANCA SNYDER</td>
<td>President</td>
</tr>
<tr>
<td>MRS. MICHAEL CARR</td>
<td>Vice President</td>
</tr>
<tr>
<td>MELANIE HOLLAND</td>
<td>Vice President</td>
</tr>
<tr>
<td>DEBRA PIPINES</td>
<td>Vice President</td>
</tr>
<tr>
<td>VICTORIA GREENLEAF KEMPNER</td>
<td>Treasurer</td>
</tr>
<tr>
<td>MRS. JAMES HALSEY BELL</td>
<td>Assistant Treasurer</td>
</tr>
<tr>
<td>MRS. THOMAS V. LEEDS</td>
<td>Past President</td>
</tr>
<tr>
<td>MRS. LOUIS ROSE</td>
<td>Secretary</td>
</tr>
<tr>
<td>MRS. HILARY DICK</td>
<td>Assistant Secretary</td>
</tr>
</tbody>
</table>

MEMBERS-AT-LARGE

<table>
<thead>
<tr>
<th>Name</th>
<th>Member Since</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kate Allen*</td>
<td></td>
</tr>
<tr>
<td>Muffie Potter Aston</td>
<td></td>
</tr>
<tr>
<td>Mrs. Alan J. Blinken</td>
<td></td>
</tr>
<tr>
<td>Tony Burch</td>
<td></td>
</tr>
<tr>
<td>Mrs. Bryan J. Carey</td>
<td></td>
</tr>
<tr>
<td>Mrs. Kevin C. Coleman</td>
<td></td>
</tr>
<tr>
<td>Mrs. Archibald Cox, Jr.</td>
<td></td>
</tr>
<tr>
<td>Jennifer Creel</td>
<td></td>
</tr>
<tr>
<td>Mrs. Michael J.A. Darling</td>
<td></td>
</tr>
<tr>
<td>Mrs. Marvin H. Davidson</td>
<td></td>
</tr>
<tr>
<td>Webb Egerton</td>
<td></td>
</tr>
<tr>
<td>Mrs. Christopher Errico</td>
<td></td>
</tr>
<tr>
<td>Ruth G. Fleischmann</td>
<td></td>
</tr>
<tr>
<td>Mrs. Lars Forsberg</td>
<td></td>
</tr>
<tr>
<td>Elizabeth Kirby Fuller</td>
<td></td>
</tr>
<tr>
<td>Mrs. Robert M. Gardiner</td>
<td></td>
</tr>
<tr>
<td>Mrs. Mark V. Giordano</td>
<td></td>
</tr>
<tr>
<td>Mrs. Thomas S. Glover</td>
<td></td>
</tr>
<tr>
<td>Eugenie Niven Goodman</td>
<td></td>
</tr>
<tr>
<td>Mrs. Peter S. Gregory</td>
<td></td>
</tr>
<tr>
<td>Mrs. Roger P. Griswold, Jr.</td>
<td></td>
</tr>
<tr>
<td>Shoshanna Gruss*</td>
<td></td>
</tr>
<tr>
<td>Alexia Hamm Ryan</td>
<td></td>
</tr>
<tr>
<td>Leslie Heaney</td>
<td></td>
</tr>
<tr>
<td>Mrs. Scott C. Johnston</td>
<td></td>
</tr>
<tr>
<td>Robyn Lane Joseph</td>
<td></td>
</tr>
<tr>
<td>Mrs. Michael Kennedy</td>
<td></td>
</tr>
<tr>
<td>Martha O’Brien Lamphere*</td>
<td></td>
</tr>
<tr>
<td>Kamie Lightburn</td>
<td></td>
</tr>
<tr>
<td>Stephanie Loeffler</td>
<td></td>
</tr>
<tr>
<td>Mrs. Roman Martinez IV</td>
<td></td>
</tr>
<tr>
<td>Mrs. S. Christopher Meigher III</td>
<td></td>
</tr>
<tr>
<td>Mrs. Richard A. Miller</td>
<td></td>
</tr>
<tr>
<td>Mrs. George F. Moss</td>
<td></td>
</tr>
<tr>
<td>Joyce L. Moss</td>
<td></td>
</tr>
<tr>
<td>Mrs. Timothy P. O’Hara</td>
<td></td>
</tr>
<tr>
<td>Jennifer Gaffney Oken</td>
<td></td>
</tr>
<tr>
<td>Mrs. Gunnar S. Overstrom, III</td>
<td></td>
</tr>
<tr>
<td>Marcie Panter*</td>
<td></td>
</tr>
<tr>
<td>Mrs. Richard T. Perkin</td>
<td></td>
</tr>
<tr>
<td>Mrs. Bambi Putnam</td>
<td></td>
</tr>
<tr>
<td>Shafi Roepers</td>
<td></td>
</tr>
<tr>
<td>Mrs. Paul C. Schorr IV</td>
<td></td>
</tr>
<tr>
<td>Mrs. Stephen C. Sherrill</td>
<td></td>
</tr>
<tr>
<td>Mrs. Sean P. Smith</td>
<td></td>
</tr>
<tr>
<td>Mrs. Paul Soros</td>
<td></td>
</tr>
<tr>
<td>Amanda Anne Cox Taylor</td>
<td></td>
</tr>
<tr>
<td>Mrs. Andrew S. Thomas</td>
<td></td>
</tr>
<tr>
<td>Mrs. Jerome L. Villalba</td>
<td></td>
</tr>
<tr>
<td>Victoria Vought</td>
<td></td>
</tr>
<tr>
<td>Naomi Waletzky</td>
<td></td>
</tr>
<tr>
<td>Mrs. Martha Webster</td>
<td></td>
</tr>
<tr>
<td>Mrs. Thomas E. Zacharias</td>
<td></td>
</tr>
<tr>
<td>Mrs. Caryn Zucker</td>
<td></td>
</tr>
</tbody>
</table>

SUSTAINING BOARD

<table>
<thead>
<tr>
<th>Name</th>
<th>Member Since</th>
</tr>
</thead>
<tbody>
<tr>
<td>Courtney Arnot</td>
<td></td>
</tr>
<tr>
<td>Mrs. Andries Bausili</td>
<td></td>
</tr>
<tr>
<td>Mrs. Andrew M. Blum</td>
<td></td>
</tr>
<tr>
<td>Dianne G. Crary</td>
<td></td>
</tr>
<tr>
<td>Mrs. James F. Curtis III</td>
<td></td>
</tr>
<tr>
<td>Mrs. James H. Dean</td>
<td></td>
</tr>
<tr>
<td>Antonia Paepcke DuBrul</td>
<td></td>
</tr>
<tr>
<td>Mrs. Thomas J. Fahey, Jr.</td>
<td></td>
</tr>
<tr>
<td>Mrs. Thomas M. Fitzgerald III</td>
<td></td>
</tr>
<tr>
<td>Mrs. Roberto de Guardiola</td>
<td></td>
</tr>
<tr>
<td>Mrs. John S. Hilson</td>
<td></td>
</tr>
<tr>
<td>Mrs. Ann F. Jeffery</td>
<td></td>
</tr>
<tr>
<td>Suzie Kovner</td>
<td></td>
</tr>
<tr>
<td>Mrs. Brian A. McCarthy</td>
<td></td>
</tr>
<tr>
<td>Mrs. Minot K. Milliken</td>
<td></td>
</tr>
<tr>
<td>Mrs. Charles H. Mott</td>
<td></td>
</tr>
<tr>
<td>Nancy Coffey Nagler</td>
<td></td>
</tr>
<tr>
<td>Mrs. Samuel F. Pryor IV</td>
<td></td>
</tr>
<tr>
<td>Mrs. Benjamin M. Rosen</td>
<td></td>
</tr>
<tr>
<td>Evelyn Angevine Silla</td>
<td></td>
</tr>
<tr>
<td>Mrs. Richard J. Sterne</td>
<td></td>
</tr>
<tr>
<td>Leith Rutherford Talamo</td>
<td></td>
</tr>
<tr>
<td>Mrs. Michael L. Tarnopol</td>
<td></td>
</tr>
<tr>
<td>Alexis Robinson Waller</td>
<td></td>
</tr>
<tr>
<td>Mrs. Douglas A. Warner III</td>
<td></td>
</tr>
</tbody>
</table>

PRESIDENT’S COUNCIL

<table>
<thead>
<tr>
<th>Name</th>
<th>Member Since</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mrs. Rand V. Araskog</td>
<td></td>
</tr>
<tr>
<td>Nina Garcia Conrod</td>
<td></td>
</tr>
<tr>
<td>Mrs. Charles A. Dana, Jr.</td>
<td></td>
</tr>
<tr>
<td>Julie Weindling Geier</td>
<td></td>
</tr>
<tr>
<td>Mrs. Richard S. LeFrak</td>
<td></td>
</tr>
<tr>
<td>Mrs. Donald B. Marron</td>
<td></td>
</tr>
<tr>
<td>Linda Gosden Robinson</td>
<td></td>
</tr>
</tbody>
</table>

PAST PRESIDENTS

<table>
<thead>
<tr>
<th>Name</th>
<th>Member Since</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mrs. Coleman P. Burke</td>
<td></td>
</tr>
<tr>
<td>Mrs. Edwin M. Burke</td>
<td></td>
</tr>
<tr>
<td>Mrs. William M. Carson</td>
<td></td>
</tr>
<tr>
<td>Mrs. Walter B. Delafield</td>
<td></td>
</tr>
<tr>
<td>Mrs. Charles H. Dyson</td>
<td></td>
</tr>
<tr>
<td>Mrs. Bruce A. Gimbel</td>
<td></td>
</tr>
<tr>
<td>Martha Victor Glass</td>
<td></td>
</tr>
<tr>
<td>Mrs. William O. Harbach</td>
<td></td>
</tr>
<tr>
<td>Alison Barr Howard</td>
<td></td>
</tr>
<tr>
<td>Mrs. Peter D. Jones</td>
<td></td>
</tr>
<tr>
<td>Mrs. Kerryn King</td>
<td></td>
</tr>
<tr>
<td>Mrs. Arie L. Kopelman</td>
<td></td>
</tr>
<tr>
<td>Mrs. Derek L. Limbocker</td>
<td></td>
</tr>
<tr>
<td>Jean Remmel Little</td>
<td></td>
</tr>
<tr>
<td>Mrs. M. Anthony May</td>
<td></td>
</tr>
<tr>
<td>Mrs. Frank A. Metz, Jr.</td>
<td></td>
</tr>
<tr>
<td>Dr. Annette U. Rickel</td>
<td></td>
</tr>
<tr>
<td>Mrs. Bijan Safai</td>
<td></td>
</tr>
</tbody>
</table>

FOUNDER

<table>
<thead>
<tr>
<th>Name</th>
<th>Member Since</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mrs. Edward C. Delafield</td>
<td></td>
</tr>
</tbody>
</table>

*indicates new member
The Society of Memorial Sloan Kettering Cancer Center

“The Society has been part of the Memorial Sloan Kettering team for nearly seven decades. We are privileged to fund projects that strengthen and enhance the mission of this extraordinary institution,” says Society President Lavinia Branca Snyder.

Supporting Research

One of The Society’s central missions is the funding of nascent research that is often too early to receive support from conventional sources. The Society has helped launch innovative investigations of young scientists and has provided an opportunity for established researchers to explore leading-edge ideas.

In 2015, The Society’s Special Projects Committee funded the research of five MSK scientists. Their projects included an investigation that modeled pancreatic cancer through gene editing in human embryonic stem cells; inducing cell death with the use of nanoparticles as an anticancer strategy; and employing genetically engineered mouse models of glioblastoma to gain insights into tumor development that can inform the development and assessment of therapies for this deadly brain cancer.

The Society’s Research Grants support the clinical and translational research projects of junior investigators, many of which go on to become permanent programs and features of MSK. In 2015, the grant program funded nine proposals. These included a study focused on investigating the molecular mechanism underlying a novel group of aggressive kidney cancers; a project exploring changes in the tumors and blood of patients with Merkel cell carcinoma, a rare skin cancer; and a study to examine methods to sensitize ovarian cancers to checkpoint blockade immunotherapy.

The Society also supports research through the Associates Committee Fall Party, which in 2015 raised funds to help launch the Pain and Palliative Care Team in MSK’s Department of Pediatrics.

The Society Campaign (formerly known as the Annual Appeal), a tradition since 1946, supports research and patient care programs through a personal letter-writing campaign. This year, the Campaign raised crucial funds for precision medicine, which seeks to understand the molecular makeup of each patient’s tumor to inform the best therapeutic strategy.

Funds raised through the Winter Lunch and Bunny Hop concluded the Associates Committee’s fundraising for the pediatric sarcoma initiative led by pediatric oncologist and sarcoma expert Paul Meyers.
Supporting Patient Care

When Society members are asked to define one of the key aims of the organization, the words “patient care” echo again and again. The group has a long-standing commitment to enhancing the patient experience by providing activities and events outside of the treatment routine.

Patient programs that support artistic expression and special projects that improve the patient environment — including visits from Big Apple Circus clowns to the Department of Pediatrics, flowers in waiting areas, and festive holiday activities throughout the year — are just a few of the ways The Society enriches the days of MSK’s patients.

For decades, some of the most celebrated Society traditions have centered on making the winter holiday season a joyful time for Memorial Hospital inpatients. The Society sponsors parties for both children and adults, complete with overflowing gift bags.

And, at one of the year’s most anticipated events, more than 200 pediatric patients — from toddlers to teens — can be counted on to party up a storm at the 25th annual Pediatric Prom in May. The event, hosted by The Society’s Children’s Committee, enables children and young adults who are being treated for cancer to celebrate with family, friends, and Department of Pediatrics’ medical and support staff.


Supporting Education

The educational programs sponsored by The Society are conducted in cooperation with the professional staff of MSK. The annual Health Education Seminar (HES) is central to The Society’s commitment to providing public education on the prevention, early detection, and treatment of cancer.

In 2015, the HES featured advances in precision imaging in cancer, focused on the Department of Radiology’s development of new molecular probes for multi-modality imaging, including MRI, PET, and optical, as well as innovative translational research in molecular imaging.

Among its other activities, The Society’s Social Services Committee funds the Fellowship Program for oncology social work, which annually allows four individuals interested in pursuing careers in social work to intern at MSK. This year, the Fellowship Program provided specialized on-the-job learning opportunities and stipends for four social work interns in their second-year masters program for a ten-week period during the summer.

1. Left to right: Former Society President Martha Vietor Glass; artist Solange Knowles, who served as a special guest DJ for the Spring Ball; and MSK Physician-in-Chief José Baselga.
2. 2015 Society Research Grants Program award recipients with MSK Physician-in-Chief José Baselga (center), Society Treasurer Victoria Greenleaf Kempner (far left), and Mrs. Glass (far right).
3. Caroling and celebrating at the 2015 adult patient holiday party.
4. Santa peruses the Christmas wish list of an MSK pediatric patient.
5. Left to right: Honorary Miracle on Madison Chair Sandra Lee, Society President Lavinia Branca Snyder, and Madison Avenue BID President Matthew Bauer at the 29th annual Miracle on Madison Avenue shopping event benefiting The Society of MSK on December 5.